

September 2018

CURRICULUM VITAE

Nancy Reau

PERSONAL INFORMATION

Office: Associate Director of Solid Organ Transplantation
Section Chief, Hepatology
Rush University Medical Center
1725 West Harrison Street POB 319
Chicago, Illinois 60612
Clinic: 312.942.8910|Office: 312.563.3901|Cell: 312.307.2280 |Fax: 312.563.2471
Nancy_Reau@rush.edu

Date of Birth: December 15, 1969

Citizenship: United States

Home Address: 11633 Diamond Court
Frankfort IL 60423

Spouse: Rajeev Puri, MD

Children:	Aria Noelle	4-20-02
	Krishan Thomas	5-26-04
	Alina Nicole	1-9-09

EDUCATION AND TRAINING

1988-1991:	Bachelor of Arts in Neuroscience Oberlin College, Oberlin, Ohio
1992-1996:	Doctor of Medicine, Cum laude Ohio State University, College of Medicine, Columbus, Ohio
1996-1999	Internal Medicine Residency Ohio State University Medical Center, Columbus, Ohio
1999-2001	Gastroenterology Fellowship Ohio State University Medical Center, Columbus, Ohio
2001-2002	Advanced Transplant Hepatology Fellowship The Johns Hopkins Medical Center, Baltimore, Maryland

BOARD CERTIFICATION

1994	USMLE Step 1
1995	USMLE Step 2
1997	USMLE Step 3
1999	American Board of Internal Medicine, Diplomate in Internal Medicine
2002	American Board of Internal Medicine, Gastroenterology and Hepatology
2006	American Board of Internal Medicine, Diplomate in Transplant Hepatology
2009	Recertification; ABIM, Diplomate in Internal Medicine
2012	Recertification, ABIM, Gastroenterology and Hepatology
2016	Recertification, ABIM, Transplant Hepatology

MEDICAL LICENSURE

Illinois Medical License Number 036-107841

PROFESSIONAL/ACADEMIC APPOINTMENTS:

Assistant Professor in Medicine Rush University Medical Center

2002-2005

Assistant Professor in Medicine University of Chicago	2005-2009
Associate Professor in Medicine University of Chicago	2010-2015
Associate Professor in Medicine Rush University Medical Center	2015-2017
Professor in Medicine Rush University Medical Center	2017-
Associate Director of Solid Organ Transplantation, Rush University	2015-
Section Chief, Hepatology Rush University Medical Center	2015-
Richard B. Capps Chair of Hepatology at Rush University	2018

HONORS, AWARDS, SCHOLARSHIPS

1990	Phi Beta Kappa, Junior Induction
1991	Sigma Xi
1992-1994	Ohio Regents Fellowship Recipient
1993	Society for Pediatric Research Student Research Program Scholarship
1995	Alpha Omega Alpha October
1995-1996	Roessler Memorial Scholarship Recipient
1995	American Pathology Chairs Pathology Honors Society
1996	Landacre Society Member
2009	America's Top Doctors – Castle-Connelly
2010	Fellow, American Gastroenterological Association
2013	American Liver Foundation, Annual Honoree Illinois division
2014	Fellow, American Association for the Study of Liver Diseases <i>FAASLD</i>
2017	Fellow, American College of Gastroenterology
2018	Richard B. Capps Chair of Hepatology at Rush University

PROFESSIONAL MEMBERSHIPS

1996	American College of Physicians
1999	American Association for the Study of Liver Diseases (FAASLD)
1999	American Gastroenterological Association (FAGA)
1999	American College of Gastroenterology (FACG)
2005	American Liver Foundation
2006	European Association for the Study of the Liver

REVIEW AND EDITORIAL EXPERIENCE

REVIEW

Journal Peer-Review:

Transplantation
 Hepatology
 Hospital Physician Gastroenterology Board Review Manual
 Alimentary Pharmacology and Therapeutics
 American Journal of Gastroenterology
 Clinical Infectious Diseases
 Liver Transplantation
 Liver International
 Journal of Clinical Gastroenterology
 Gastroenterology
 Journal of Infectious Diseases
 BMJ Point of Care, published by the BMJ Publishing Group
 Journal of Viral Hepatitis
 Therapeutic Advances in Gastroenterology
 Digestive Diseases and Sciences
 BioMed Central

Journal of Hepatology
 Antiviral Research
 Consumer Reports Best Buy Drugs - Hepatitis C medications
 Antiviral Therapy
 Thomson Reuters' Drug Profiles
 Journal of the International Association of Providers of AIDS Care
 Journal of the American Society of Nephrology
 Medscape Education
 Pharmaceuticals
 Pharmacogenomics
 AGA Institute's Technical Review

Grant-Review:

NIH: Special Emphasis Panel RFA-DK-14-019: Studies of HIV in Digestive Diseases Limited to Gastrointestinal Mucosal Immunology and Liver Diseases (R01)
 NIH: RFA-DK-15-068: NIDDK Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34) July 2016
 PAR-18-415: NIDDK Multi-Center Clinical Trial Cooperative Agreement (U01 Clinical Trial Required) May 2018

NIDDK/NIH:

Ad hoc member Executive Secretary of the Board of Scientific Counselors Spring 2018

EDITORIAL

2010-2015	Editorial Board: <i>World Journal of Hepatology</i>
2010-2013	Section Editor with Stephen Harrison Current Hepatitis Reports: Complex Clinical Issues Volume 9, Issue 1, March 2010 Volume 10, Issue 1, March 2011 Volume 11, Issue 1, March 2013 Volume 12, Issue 1, March 2013
2013-2017	Section Editor with Andres Cardenas, MD Current Hepatology Reports: Management of the Cirrhotic Patient
2010-current	Editorial Advisory Board MedScape Gastroenterology
2011	Section Editor with Fred Poordad <i>Clinical Gastroenterology</i> Primary Liver Cancer: Surveillance, Diagnosis and Treatment
2011-16	Editorial Board <i>Hepatology</i>
2012	Oxford American Infectious Disease Library: Hepatitis C. Jensen DM and Reau N, eds. Oxford University Press, New York, 2013.
2014	Editorial Board Member: Journal of Hepatitis Research
2015	Clinical Liver Disease AASLD: Guest Editor for HCV-related topics
2015-	HCV Next Editorial Board
2016	Clinical Liver Disease AASLD: Associate Editor
2016-2018	Co-Chief Medical Editors of Healio Gastroenterology
2017-22	Clinical Liver Disease Editor in Chief
2018	Oxford American Infectious Disease Library: The New Hepatitis C. Reau N and Jensen DM, eds. Oxford University Press, New York, 2018.

CLINICAL PRACTICE

I am currently part of a subspecialty academic department. I am 75% clinical and 25% administrative. My clinical practice is predominately outpatient consisting of seventy five percent general hepatology and twenty five percent pre/post liver transplantation. I see patients both at our campus as well as several outreach

locations. Our general hepatology patients are an equal combination of routine liver diseases as well as complicated tertiary care, including management of liver transplantation. Twelve weeks of the academic year I rotate on the inpatient hepatology service. I am involved clinical research both investigator driven as well as industry sponsored.

ADMINISTRATIVE / COMMITTEE WORK

Intramural

2007	South Chicago Dialysis Centers Consultation for HBV screening and control
2009-11	Internal Scientific Advisory Panel (ISAP) consultant
2009-11	Presenter: Internal Scientific Advisory Panel (ISAP)
March 2010	Department of Medicine, Fifth Annual Junior Faculty and Fellow Research Day: Abstract Judge
2012	Lunch & Conversation for Women Faculty, Speaker Part-Time Career Options- How to make it Work January 24
2012	TEE Disinfection Protocol Review, University of Chicago
2013-15	Hepatology Faculty Recruitment Committee, University of Chicago
2015	Medical Director Hepatology Clinical and Translational Research, University of Chicago
2015-	Associate Director of Solid Organ Transplantation Rush University
2015-	Section Chief, Hepatology Rush University Medical Center
2016-	Reviewer Rush Pilot Projects
2017-	Infectious Disease Chief, Search Committee
2018	Reviewer Rush Bone and Joint Proposals

Intramural Curriculum Development

2006-2010	University of Chicago Hepatology Journal Club
2008-2011	Nurses Educational Series Administrator
2015-	Clinical Education Series, Hepatology Department

Regional

Medical Advisory

2003	Roche PEGASYS® GE/Hepatology Regional Advisory Board June 27-29
2004	Roche PEGASYS® GE/Hepatology Regional Advisory Board October
2005	Chronic Hepatitis B Advisory Forum, Approaches to Managing and Treating Chronic Hepatitis B BMS February 8,
2006	Gilead Sciences: Hepsera® Regional Consultancy Meeting March 29 Gilead Sciences: Hepsera Regional Advisory Board June 22
2008	Gilead Sciences: Local Advisory board Chicago, IL May 13 Practitioner Advisory Forum hosted by Vertex Pharmaceuticals Chicago, IL Friday, June 13, 2008 PEGASYS® Advisory Board Meeting Palo Alto, CA July 10-11, 2008
2010	Three Rivers Pharmaceuticals Chicago Physician Advisory Board Meeting Chicago, IL June 18 Three Rivers Pharmaceuticals Virtual Advisory Board October 25, 2010 Vertex Regional Advisory Board Meeting December 16, 2010
2011	Vertex Regional Advisory Board, December 7, 2011 Chicago
2014	AbbVie Regional HCV Advisory Board, Co-Moderator BMS Hepatitis C Regional Clinical Forum November 13, 2014 Intercept Regional Medical Advisory Board Faculty November 19, 2014 Moderator NASH

- 2015 Janssen Therapeutics Regional HCV Treaters Advisory Board March 21, 15
 Gilead Sciences Regional Advisory Board:
 Current trends of LDV/SOF use in clinical practice June 12
- 2016 AbbVie Post-DDW Medical Advisory Board; Faculty June 18 Chicago
 Co-Chair Medical Advisory Committee (MAC) Illinois Chapter American
 Liver Foundation (ALF) {2016-2018}
- 2018 Dova Pharmaceuticals Advisory Thrombocytopenia

Regional Committee and Program Development

- 2001-2002 Johns Hopkins Gastroenterology Web Site Committee Member and Author
 Alcoholic Liver Disease Posted 2002
 Hemochromatosis Posted 2002
- 2005-2014 American Liver Foundation, Illinois Board of Directors
 President 2009-2012
- 2005 Co-Founder of the Liver Health Center of Illinois
- 2005-2010 American Liver Foundation, Illinois Chapter
 Hepatitis B Strategic Task Force
- 2005-2006 American Liver Foundation, Illinois Chapter Strategic Planning Committee
- 2007- ALF Illinois Medical Advisory Committee Member
- 2008-2011 ALF Illinois Board of Directors, Vice President
- 2010 ALF Illinois Search Committee for Divisional Vice President
- 2010 ALF Illinois Spring Benefit Committee, Taste of Chicago
- 2012 ALF Great Lakes Division Vice President, Search Committee Member

Regional Curriculum Development

- 2006-2015 Instructor for Olivet Nazarene University,
 GI athletic training course: General GI and Nutrition Review

National/International:

Medical Advisory:

- 2006** Gilead Post-EASL Scientific Debrief Meeting Vienna, Austria April 29
 Gilead Sciences: Pharmaceutical Representative National Training, Expert
 Case Facilitator, Chicago IL June 13
 Gilead Sciences: Treatment Strategies in Chronic Hepatitis B
 August 21 Foster City, CA
- 2007** Gilead Post-AASLD Scientific Debrief Meeting Boston, MA October
 International Forum on Resistance in the Treatment of Hepatitis B;
 March 2-3 Chicago, IL
 Gilead Sciences: Hepsera® Antiviral Resistance Summit Advisory Board
 March 24-25 New York, NY
 Gilead Post-EASL Scientific Debrief Meeting Barcelona, Spain April 15, 2007
 Abelson Taylor, medical advertising and marketing for hepatitis C therapy
 May 25 Chicago, IL
 GAIN HBV: Gilead Advisory Program: Insights into Nucleos(t)ides for
 HBV. December 1 Santa Monica CA
- 2008** Gilead Post-AASLD Scientific Debrief Meeting Boston November 6 2007
 Gilead Post-EASL Scientific Debrief Meeting Milan, Italy April 27
 Gilead Post-AASLD Scientific Debrief Meeting San Francisco CA November 4
- 2009** Nexavar® Advisory Board: Perspectives in HCC Management Chicago, IL April 18
 Gilead Hepatitis National Advisory Board Meeting Santa Monica, CA June 27
- 2010** Panel Participant: HCV Expert Panel PEGASYS National Sales Meeting, Las Vegas

- National Advisory Board Meeting-Genentech Palo Alto, CA June 2010
 ASK Advisory Board ASK Hepatitis B Gilead Sciences, New York, NY
 Nexavar HCV Web-Based Advisory Board Meeting December 1
2011 Vertex National Sales Meeting, Miami FL February 2011
 Panel and Presentations:
 Current HCV Management and the Changing Paradigm
 EASL HBV Debrief Advisory Panel Berlin, Germany April 2nd
 Moderator: Hepatitis C Commercial Council meeting *"Exploring the Key Therapeutic Decision-Points in HCV: Current and Future Perspectives"* April 29-30, 2011, Dallas, TX
 Faculty: Content Development Advisory Board for the Telaprevir Speakers Bureau Faculty post launch Chicago IL May 7
 Chairperson: PEGASYS Nurse Practitioner, Physician Assistant Advisory Board July 16th in New York City
 HCV US Virtual Advisory Board for BMS, Chair and Presenter, October 26
 November 3 Pre-AASLD Gilead Advisory Board, San Francisco
 Market Research Consultation, ALIGN2ACTION, Inc.
 Market Research Consultation MedPanel HCV
 Market Research Consultation, Physician PC New Treatments in Hepatitis C
 Expert Opinion Discussion: Defined Health PSC
 Expert Opinion Discussion: ClearView Healthcare, HCV
2012 INCIVIK National Sales Meeting, Las Vegas January 25
 KOL Panel Discussion, Faculty and Speaker Training
 Pegasys Speaker Training, Faculty Chicago, February 25, 2012
 INCIVIK Speaker Training, Faculty, February 25, 2012
 WebEx February 27 and March 5
 Janssen Clinical Affairs HCV Advisory Board, Jersey City, NJ May 10
 Abbott Advisory Board HCV in Children San Diego, CA May 20
 Vertex National Advisory Board, Cambridge MA August 30
 HCV Advisory Board-Kadmon Pharmaceuticals NYC, NY Oct 6
 Janssen Therapeutics National Hepatitis C Expert Advisory Board
 Dallas TX December 8
2013 Idenix Hepatitis C Scientific Leadership Ad Board, LA, CA February 1
 Market Research Consultation, MedPanel. HCV Amsterdam April
 Market Research Consultation, MedPanel HCC May
 Market Research Consultation, Schlesinger HCV May
 Gilead Post-EASL Advisory Program Houston TX May
 Janssen Therapeutics Commercial National Hepatitis C Expert Advisory Board June 2013 New Jersey
 Janssen Services Medical Affairs HCV National Clinical Advisory Board
"Phase 3b/4 Study Plans" August 1, 2013. Chicago IL
 American College of Physicians (ACP) Smart Medicine, Fatty Liver Module
 Idenix Global Advisory Board, HCV development
 US National Advisory Committee, Gilead Sciences (HCV)
 AbbVie HCV National Executive Advisory Board
2014 AbbVie HCV National Executive Advisory Board
 US National Advisory Committee, Gilead Sciences (HCV)
 Idenix Global Advisory Board, HCV development
 Salix: Continuity of Care for Patients Living with Hepatic Encephalopathy
 London, England April 11
 US National Advisory Post EASL Content Development; Gilead April 17

Idenix: BOD Invitation: The State of HCV Therapy June 2014 Boston
 Janssen Services HCV National Advisory Board June 2014
 Quest Diagnostics; Faculty Consultant on the development of an HCV
 Speaker Slide Deck
 Gilead Medical Advisory: HCV Screening and Linkage to Care
 Presentation: The impact of the CDC/USPSTF screening guidelines
 July 31, 2014 San Francisco
 Accordant, CVS Caremark Company, Client Summit: Changing Paradigm of
 HCV Treatment. Sept 16, 2014 Greensboro, NC
 AbbVie Next Generation Global HCV Development Advisory Board
 BMS National Advisory Board Liver Disease Collaborative Institute
 Accordant, CVS Caremark Medical Advisory Board for hepatitis C
2015 Merck National Advisory Committee, Hepatitis C
 US National Advisory Committee, Gilead Sciences (HCV)
 AbbVie HCV National Executive Advisory Board
 AbbVie Next Generation Global HCV Development Advisory Board
 Quest Diagnostics Liver Fibrosis Advisory Board Santa Monica, June 2015
 Taking Action from Insights to Empower Better Health
 Bristol-Myers Squibb Daclatasvir Launch, Miami July
 Janssen National HCV KOL Advisory Board, New Jersey July 17
 US National Advisory Committee, Gilead Sciences (HCV)
 Quest Diagnostics Hepatitis Advisory Board, November 2015
 AbbVie HCV Medical Advisory Board, Data presentation
 Honolulu, HI November 2015
 Gilead Sciences HCV MAAP (Medical Affairs Advisory Program): HCV
 Screening and Linkage to Care; Foster City December 16-17
 Accordant, CVS Caremark Medical Advisory Board for hepatitis C
2016 Abbvie Global HCV Advisory Board, Paris France January 12
 Merck, HCV US Strategic Advisory Board
 Women with HCV Advisory Board, AbbVie, Barcelona Spain, April
 Intercept OCA Content Development Steering Committee
 AbbVie No Numbers Long Range Plan (NNLRP) Hackathon
 BMS LDCI (Liver Disease Collaborative Institute) National Advisory Board
 Quest Diagnostics Hepatitis Initiatives
 Accordant, CVS Caremark Medical Advisory Board for hepatitis C
2017 Abbvie National Post-AASLD Advisory Board, Moderator Tampa, FL
 January 28
 Merck HCV Global Commercial Strategy Board
 AbbVie HCV Executive Advisory Board
 Gilead HBV and HCV EASL Scientific Debrief 4/22
 CCO (Clinical Care Options): Independent Conference Coverage of EASL
 American Transplant Congress (ATC) session moderator April 30
 AASLD/DDW Session Moderator: HCV Therapeutics II
 Quest Diagnostics (hepatitis) Medical Affairs Meeting May 8
 Gilead Medical Affairs Advisory "HCV Evolving Landscape and Data Gaps"
 June 9, Foster City, CA
 Hepatitis C Global Therapeutic Expert Forum NJ June 23
 Accordant, CVS Caremark Medical Advisory Board for hepatitis C
2018 AbbVie HCV Global Steering Committee
 Gilead Sciences, HCV Elimination Advisory Board Berlin February 1
 Accordant, CVS Caremark Medical Advisory Board for hepatitis C

Practice Point Communications, Course Director CME *Clinical Viewpoints®: A CME Lecture Series for Thrombocytopenia in Chronic Liver Disease*
 NIH/NIDDK
 Gilead Liver Diseases US National Advisory Board August San Francisco
 Dova Medical Advisory

National Committee and Program Development

2007	American Transplant Congress Abstract Review Committee
2007-2010	AASLD Practice Guideline Committee, Member
2008-2011	ACG Women's Committee, Member
2008-	AGA/DDW Abstract Review Committee
	Liver and Biliary Section: Clinical Hepatitis: Etiology, Diagnosis, Management, and Natural History
2009-	AASLD HBV SIG Committee, Member
2009-11	ALF National Board Illinois Delegate Assembly Member
2010-12	ALF National Chairman's Advisory Council
2010	ALF National Conference Planning Committee for the ALF Leadership Conference and Annual Meeting of the <i>Delegate Assembly</i>
2010	AASLD Practice Guideline Committee Representative
	Guidelines International Network (G-I-N) Conference 2010
	Chicago IL August 2010
2010-11	AASLD Practice Guideline Committee, Member
	Term extended by one year at the chairman's request
2010-16	CLDF (Chronic Liver Disease Foundation) Content Development and Review
2011	American Physician Institute for Advanced Professional Studies
	Internal Medicine Recertification Course Los Vegas, Nevada March 2011
2011-13	ALF National Strategic Planning Committee
2011-13	ALF National Board of Director, Member
2011-2014	AASLD Public Policy Committee, Member
2011-2014	AASLD Federal Agency Liaison Committee, Member
2011	HCV Council 2011: An Evidence-Based Appraisal of
	New Therapies-Defining Best Practices to Optimize Outcomes" May 2011, Chicago
2011-14	ACG abstract review: Liver Diseases
2011-14	AASLD abstract review: Hepatitis B: Virology and Diagnostics
	Review for both AASLD and DDW
2012-2014	AASLD Public Policy Committee, Committee Chair
2011-12	ALF National Innovation Council, Co-Director
2011-	Medscape Gastroenterology Editorial Advisory Board
2011-	Medscape Education Advisory Board for Gastroenterology
	Medscape Education Outcome assessment, HCV 2012-2014
	Medscape Education Outcome Assessment, HBV 2013
2012-	Steering Committee - Medscape Clinical Course in HCV
	MedScape HCV Steering Committee, Chair 2013, 2014
2012	International Hepatitis Education Program (IHEP) at the
	International Liver Annual Meeting of the American Association for the Study of
	Liver Disease (AASLD) Boston, MA November, 2012
2013-	Medivo Medical Advisory Board
2013	International Hepatitis Education Program (IHEP) at The
	International Liver Meeting 48 th Annual Meeting of the European Association for the
	Study of the Liver (EASL) Amsterdam, Netherlands, April 24-28, 2013
2013	Consultation DRAFTFCB HealthCare March 2013

2012-14 2013	PriMed Annual Conference Series Viral Hepatitis Track Director <i>American Physician Institute for Advanced Professional Studies</i> , CME-Accredited board preparation course. Program Editor and Liver Module Author.
2013-	Contributing editor @Point of Care360: Hepatitis C Edition Overview/Currently Approved Antiviral Agents
2013	Steering committee member for the CME activities titled, "HCV VOICE: Optimizing Virological Outcomes with Integrated HCV Education"
2013	Content development for 26-city liver CME meeting series HCVVOICE.com
2013-15	MedScape Steering Committee Chair; <i>Clinical Course in HCV</i> National American Liver Foundation; National Medical Advisory Committee (NMAC) Co-Chair
2013	International Hepatitis Education Program (IHEP) to be held at the International Annual Meeting of the American Association for the Study of Liver Disease (AASLD) Washington DC November, 2013
2013-16	ACT-on-HCV; AASLD educational program, content development and presentation AASLD-IDSA Hepatitis C Guideline, Author Co-Lead: HCV Screening and Linkage to Care (First Draft) Co-Lead: Whom and When to Treat (First Draft) Co-Lead: Treatment Naive (Revision Draft) Co-Lead: Special Populations, Renal (Revision Draft) Co-Lead: Resistance (First Draft)
2014	HCV Council (Duke CME): Workshop Leader
2014-17	American College of Gastroenterology (ACG) Training Committee
2014	HCV Action Steering Committee, Primary Care Education
2014	National American Liver Foundation, 2014 Distinguished Scientific Achievement Award Review Committee
2014	CLDF-HCV Advances Development Meeting Breakout leader for slide content review
2014	AASLD representative: PCORI hosted stakeholder workshop: Hepatitis C Interventions and Clinical Management Strategies for Hepatitis C Infection Oct 17 Washington DC
2015-17	AASLD Hepatitis C Special Interest Group Steering Committee
2014	CLDF Annual Content Development Meeting November 7, 2014 Boston MA
2014-15	National American Liver Foundation (ALF) Research Awards Committee National American Liver Foundation (ALF) 2015 Distinguished Scientific Achievement Award Review Committee
2015-	Chairperson of Clinical and Content Development and Review for the Chronic Liver Disease Foundation (CLDF)
2015-16	Gilead Sciences, HCV U.S. National Advisory Committee (UNAC) UNAC EASL Debrief Advisory Meeting, Vienna Austria April 2015
2015	Hepatic Encephalopathy (HE) Guidelines Advisory Board Meeting, Vienna Austria April 2015
2015-18	American Board of Internal Medicine (ABIM) Gastroenterology Board Exam Committee
2015	NIH/NIDDK: Special Emphasis Panel review applications received in response to RFA-DK-14-019: Studies of HIV in Digestive Diseases Limited to Gastrointestinal Mucosal Immunology and Liver Diseases (R01)
2016	Simply Speaking Hepatitis CME, content development faculty Clinical Management of HCV in Patients with Renal Disease.

2016	NIH/NIDDK: Special Emphasis Panel review applications received in response to PAR-15-068: NIDDK Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34)
2016	AGA's (American Gastroenterological Association) HCV Pathway Taskforce
2016-	Alliance to Eliminate HIV/HCV Coinfection (AEH ² C) Medical Board
2017	2017 Simply Speaking Hepatitis Content Development (CME)
2017	AbbVie US Medical HCV Leadership Council, Chair
2017	Program Chair for the 6 th International Conference on Viral Hepatitis (ICVH)
2017-19	American Board of Internal Medicine (ABIM) Gastroenterology Specialty Board
2018-19	Vice-Chair of the AASLD Hepatitis C SIG
2017	Moderator DDW Topic Forum HCV Therapeutics
2017	HCV Course Director PRIME " <i>Second Annual Payer and Provider Discussions: Overcoming Discordance in HCV and HIV Treatments</i> " in partnership with the American Gastroenterological Association (AGA) and the Academy of Managed Care Pharmacy (AMCP)
2018	American College of Gastroenterology (ACG) North American GI Fellows Conference Faculty March Orlando, FL
2018	Gilead Liver Diseases US National Advisory Board San Francisco CA August 23

Research Consultation:

2007-10	Research Consultation: Defined Health Intravenous and subcutaneous Immunoglobulin therapies PBC and anti-fibrotics
2010-	Research Consultation: Decision Resources: NASH
2000-Current	Research Consultation: Guidepoint Global HCV, HBV, Hepatic Encephalopathy
2009-	Research Consultation: MedPanel LLC: HCV
2008-	Research Consultation: Schlesinger Associates, Inc HBV, HCV, Liver transplantation
2010	Medical marketing research consultancy: Gen LLC: HBV
2009-10	Research Consultation: Easton Associates, LLC HCV Therapeutic Vaccine
2014-	Research Consultation: Cerenti Group- HCV
2014-	Gilead Trial Guidance and Publication Committee (TGPC) for the GS-US-342-1139 Phase 3 study of SOF/GS-5816
2015-	Research Consultation: Sociable Data- HCV and HBV treatment issues and therapies
2015-	RxOI Insights
2016-	RDS Consulting
2018	MKO Global Partners Engagement (NAFLD)
2018	Boston Healthcare

LEGAL ADVISORY

2006	Holly v. DaVita IN
2008	Ronald Knittle v. Barnes-Jewish Hospital , et al. [SPVG1.FID290338]
2011	48171 CRUMBLEY (LARRY) V. CITY OF ORLANDO
2012	v. MD and hospital (AFLP)
2016	Redmond v. United States ; Detroit, MI
2016	Susan Prebish v. Ari Wiesen, MD , Cleveland OH

VISITING PROFESSORSHIPS

- 2015 University of Wisconsin School of Medicine and Public Health (UWSMPH) in Madison, Wisconsin, Gastroenterology and Hepatology
- 2016 The Ohio State University 3rd Annual Fred B. Thomas Memorial Reception & Lecture October 26
Internal Medicine Grand Rounds: *HCV: After the Cure* October 27
Gastroenterology Grand Rounds: Resistance in HCV the Good the Bad the Necessary

PRESENTATIONS**Intramural Presentations**

- 2003** RUSH Medical Center Grand Rounds: Sick Cell Hepatopathy
RUSH Medical Center Grand Rounds: Alpha-One Antitrypsin Deficiency May 29, 2003
- 2005** RUSH Medical Center Grand Rounds: NAFLD, It's just a little fat?
- 2007** University of Chicago OB/GYN grand rounds: Viral Hepatitis and Pregnancy February 1
If it sounds like a duck it may be a zebra: Hepatopulmonary Syndromes
Gastroenterology Clinical Conference May 10,
University of Chicago Liver Transplantation PATIENT FORUM
Post-transplant health maintenance, How to keep your new liver healthy May 22
University of Chicago, Pulmonary Grand Rounds: Ascites and SBP July 13, 2007
University of Chicago Gastroenterology Research Conference:
The Pitfalls of Pivotal Trials September 20
University of Chicago, Medical Grand Rounds:
What's the big deal about a little fat? NAFLD. November 27
University of Chicago OB/GYN grand rounds:
Viral Hepatitis and Pregnancy December 20
- 2008** Internal Medicine Hospitalist teaching series Interpretation of LFTs February 11
Gastroenterology Clinical Conference
HBV and ESRD: Does the kidney really matter? May 1
- 2009** Internal Medicine Hospitalist teaching series Ascites and SBP, June 8
- 2010** University of Chicago Gastroenterology Research Conference:
What are the holes in the screen? HCC Surveillance March
Gastroenterology Clinical Conference
When does size matter, benign liver lesions? March 2010
- 2011** University of Chicago Gastroenterology Clinical Conference:
AMA negative PBC, A Diagnosis for Concern January
Internal Medicine Hospitalist teaching series Ascites and SBP, February 24
- 2013** ID Clinical Conference with UC and UIC HIV HCV Co-infection May 9
Internal Medicine Grand Rounds: Viral Hepatitis C, Striving toward Nirvana October
Clinical Therapeutic Seminar Series- Viral hepatitis
- 2015** Rush University Medical center Grand Rounds:
HCC and the Future of Biomarkers, November
- 2016** GI Grand Rounds: HCV Guidelines, an update February 4

Regional Presentations

- 2003** GI Nurses Forum: Depression and its management with HCV and Hepatitis Therapy
Hoffman Estates, IL
- 2005** New Insights into the Management of Hepatitis C, CME Primary Care Series
Chronic Liver Foundation 1.5 hr CME
Chicago, IL May 2, 2005
Chicago, IL August 9, 2005
Chicago, IL November 2, 2005

- Treatment of Chronic Hepatitis B Disease Merrillville, IN September 14, 2005
 Understanding Chronic Hepatitis B Disease Homewood, IL October 25, 2005
- 2006** New Insights into the Management of Hepatitis C, CME Primary Care Series
 Chronic Liver Disease Foundation Chicago, IL January 17, 2006
 “Treatment of Chronic Hepatitis B” Chicago, IL February 28,
 American Liver Foundation, LEARN Audio Conference:
 Treatment Options for HCV CME Chicago, IL March 1
 “Treatment of Chronic Hepatitis B” Merrillville, IN March 21
 American Liver Foundation, Understanding Hepatitis C Town Hall Meeting
 Hepatitis C Virus: Historical Perspective, Epidemiology, and Natural History
 Northwestern University March 25
 What’s the matter with a little Fat?
 Gastrointestinal Research Foundation Women’s Board Meeting
 Glenview, IL May 16, 2006
 Hepatitis B Academic Case Presentation and Discussion
 Chicago IL May 16, 2007
 Chicago, IL August 17, 2006
 Chicago, IL December 7, 2006
 Target Hepatitis B and C, CME Primary Care Series
 Chronic Liver Foundation 1.5hr CME
 Chicago, IL June 27, 2006
 Chicago, IL November 7, 2006
 Chicago, IL November 28, 2006
 “Understanding Chronic Hepatitis B Disease”
 Chicago IL August 2, 2006
 Frankfort, IL November 8, 2006
 Hepatology Roundtable: Multiple presentations of Cholestasis
 Merrillville, IN September 20th
 AGA Hepatitis B; State of Science Regional Workshop: Role of Antiviral Therapy
 Chicago IL CME October 14, 2006
 Northwest Suburban Gut Club: Hepatitis B CME Update
 Schaumburg Illinois November 2, 2006
- 2007** Hepatitis B: Case Presentation and Update for Nurses Chicago IL February 22
 Hepatitis B, The Basics: Healthcare Provider's Guide to Chronic Hepatitis B
 Chicago APAMSA Update
 Chicago, IL February 27, 2007
 Hepatitis B Academic Case Presentation and Discussion
 Chicago, IL March 15, 2007
 American Liver Foundation, Understanding Viral Hepatitis Town Hall Meeting
 An update on Chronic Hepatitis B
 University of Illinois at Chicago, Chicago, IL March 31, 2007
 Hepatitis B: Case Presentations Area GI fellows and residents
 Chicago, IL May 29, 2007
 InTime TV Internet TV talk show - Insights in Medicine CME
 Fatty Liver Disease June 2007
 Grand Grounds Christ Hospital: NAFLD: What’s the big deal about a little fat?
 October 25
 Nutrition and Liver Disease University of Chicago Patient Forum
 Tinley Park, IL October 27
 Resurrection Health Care Medicine Grand Rounds:
 Non Alcoholic Fatty Liver Disease. A CME Update, December 13, 2007

- Hepatitis B and the growing concerns for Drug Resistance
Cincinnati, OH December 17, 2007
- 2008** Interpreting Liver Test Abnormalities
Liver Diseases: Above and Beyond the Basics for Primary Care Physicians.
American Liver Disease Foundation Primary Care Physicians Program
Northern Illinois University-Naperville Campus, Naperville, IL
6 CMEs Saturday, February 23
- The growing importance of fatty liver disease and barriers to therapy
GIRF (GastroIntestinal Research Foundation) Board Meeting
Chicago IL February 21, 2008
- Hepatitis B: An Overview for MDs and Nurses
Chicago IL April 2, 2008
- Hepatitis B and the growing concerns for Drug Resistance
Aurora Sinai Medical Center Milwaukee, WI June 9, 2008
- Hepatitis B: Case Presentations
BioScript Pharmacy Milwaukee, WI June 9, 2008
- Hepatitis B and the growing concerns for Drug Resistance
Ohio State University Columbus, OH September 4, 2008
- Hepatitis B; Case presentations
Ohio State University, Gastroenterology Fellow's Morning Report
Columbus, OH September 5, 2008
- Hepatitis B, the basics: Healthcare Provider's Guide to Chronic Hepatitis B
Chicago Department of Public Health Chicago IL September 17, 2008
- PBC and PSC: American Liver Disease Foundation Liver Diseases: Town Hall Meeting
University of Chicago, Chicago IL September 27, 2008
- HCC: The New Epidemic Moderator
Featuring Visiting Professor of Medicine K. Rajender Reddy, MD
Presented by The American Liver Foundation, Illinois October 2, 2008
- 2009** Midwest Gastroenterology Review 2009
Personalized Approach to the Management of Chronic Viral Hepatitis December 12
- 2010** Consequences of Portal Hypertension
Riverside Hospital Resident and Fellow Lecture Series
Riverside, Kankakee August 2, 2010
- HBV Lunch and Learn Meeting: Johns Hopkins CME 1 CE
Swedish Covenant Hospital Chicago, IL November 4th, 2010
Christian Community Health Center Chicago IL November 18th, 2010
- Society of Future Physicians, UIC
My role as a Hepatologist, Sponsor: ALF October 30, 2010
- 2011** HBV Lunch and Learn Meeting: Johns Hopkins CME 1 CE
Fox Valley Dialysis Aurora, IL April 6, 2011
Tri-Cities Dialysis Geneva, IL April 12, 2011
Chicago Board of Health Department May 29, 2011
Reproductive Health Associates, Hazel Crest May 29, 2011
- 2011 Hepatology Centers of Educational Expertise (HCEE) CME series
May 3, 2011 Chicago IL
- HCV Roundtable:
Retreatment of Patients Infected With Hepatitis C Virus
Paramus, NJ September 7, 2011
- HCV Roundtable:
Chronic HCV Treatment Algorithm: Clinical Decision Points
Brookfield, WI September 20, 2011

- HCV Roundtable:
Decision Making for Chronic HCV-Infected Patients - Influence of Patient Diversity
Glenview, IL October 4, 2011
- 2012** Chronic Hepatitis B Mentorship Hub Program
CHiP CME Program, January 27, 2012
CHiP CME Program, May 17, 2012
CHiP CME Program, September 20, 2012
Chronic Liver Disease Foundation, CME Regional Conference Series, Faculty
HCV Series January 19, 2012 St. Louis MO
Cirrhosis complications and HCV Series October 2, 2012 Chicago, IL
Midwest Viral Hepatitis Conference, CDC funded CME
Viral Hepatitis: Understanding Disease Burden and Midwest Disparities
May 11, 2012 Chicago IL
Vertex Regional Advisory Board, HCV
Moderator- Dallas TX June 14
Moderator-Chicago IL June 16
HCV among the African American Community, WVON radio health spot July 7
Non-branded Peer Discussion, INCIVEK Combination treatment in Clinical Practice
Bayside, NY August 14
NYC, NY August 15
Midwest Clinicians' Network, CME Webinar
The diagnosis and management of HBV October 12
AGA - HCV CME Symposia "Improving Care and Outcomes for Patients with
Hepatitis C Virus Infection." Chicago IL November 15
- 2013** American Medical Forum: CME "Update on Hepatitis"
June 2013 Northbrook IL
October 2013 Chicago IL
Midwest AIDS Training and Education Center [MATEC]
"Update in New Treatments for HCV Therapy" September Chicago
HCV VOICE CME Meeting Series: Content and Faculty
Birmingham, AL October 2013
Chicago, IL October 2013
Rochester, MN November 2013
Denver CO December 2013
Shreveport AL January 2014
HCV Regional Pri-Med CME Series, Content Development and Faculty:
October 2013, Chicago IL
December 2013, Baltimore MD
Chronic Liver Disease Foundation, CME:
Current Insights into the Management of Hepatic Encephalopathy
November 2013 Chicago IL
- 2014** CCO (Clinical Care Outcomes) HCV Annual Regional Meeting, CME
Panelist San Francisco May 2014
CLDF (Chronic Liver Disease Foundation):
Current Perspectives into the Management of Hepatic Encephalopathy,
CME (1.5), June 2014, Chicago IL
P² Peer to Peer HCV CME Mentoring Program
Teleweb Program May 2014
Teleweb Program August 2014
Teleweb Program October 2014
American College of Gastroenterology (ACG) Women in Gastroenterology Forum

- Management of Hepatitis C: New Drugs and New Paradigms
September Chicago, IL
- American College of Gastroenterology (ACG): Hepatitis School,
September Chicago IL
“Update on HBV therapy”
“HCC and HCV”
“Treating HCV in patients with cirrhosis”
- American Medical Forum: CME “Update on Hepatitis: HBV and HCV”
June 2014 Chicago IL
October 2014 Chicago IL
- CLDF HCV Advances CME Meeting Series
Chicago IL October 2014
TeleWeb December 2014
- IAS-USA Regional CME Program Faculty
An Intensive Workshop On □Evolving Strategies In Viral Hepatitis
Management Boston October 2014
- PRIME-HCV CME Meeting Series: Faculty
Patient-centered Strategies & Evolving Treatment Interventions in the Combat
with HCV
Seattle WA December 6, 2014
- 2015** HCV VOICE II CME Meeting Series: Faculty
New Orleans, LA January 22, 2015
Chicago IL February 24, 2015
- PRIME-HCV CME Meeting Series: Faculty
Patient-centered Strategies & Evolving Treatment in the Combat with HCV
Tempe, AZ February 21, 2015
Cincinnati OH March 7, 2015
Chicago IL August 22, 2015
Ypsilanti MI September 22, 2015
- PRIME and AGA-HCV CME Webinar: The Challenging HCV Patient
July 14, 2015
July 23, 2015
July 27, 2015
- Perspective on HCV Product Launches and Patient Access Advisory Board: Faculty
Dallas, TX April 29, 2015
- CLDF HCV Advances CME Meeting Series
Chicago IL May 2015
Chicago IL November 5, 2015
Chicago IL November 24, 2015
- Clinical Care Options (CCO) CME/CE Workshop
Evolving HCV Management in Harder-to-Treat Populations
Chicago IL May 2015
Miami FL June 2015
Chicago IL September 2015
- Second Annual Update in Hepatology, Gastroenterology and Transplantation
University of Pittsburgh School of Medicine (CME) May 2015
Autoimmune Hepatitis: Where Do We Go After Prednisone?
- Annual Clinical Care Options HIV and Hepatitis C CME Symposium
Panelist/discussant “*Key Management Decisions in HCV*”
NYC, NY June 6, 2015
- University of Chicago CME:

- Best of the Annual Conference in Digestive Diseases 2015
- Hepatology Moderator
- Lecturer: HCV Therapy in 2015
- Accordant In-Service Review: HCV June
- IAS-USA (International Antiviral Society-USA) CME Conference
 - Management of Hepatitis C Virus in the New Era: Small Molecules
 - Bring Big Changes: Overview of the liver for the non-hepatologist
 - Atlanta GA September 24, 2015
- GALA (GI and Liver Association of the Americas) CME conference
 - HCC and future of biomarkers Chicago IL September 25, 2015
- Silver Cross Hospital Internal Medicine CME symposium
 - Hepatitis C, an update for primary care Joliet IL September 26, 2015
- IAS-USA (International Antiviral Society-USA) CME Conference
 - Management of Hepatitis C Virus in the New Era: Small Molecules
 - Bring Big Changes: Fatty Liver Disease, an Overview
 - San Francisco CA October 15, 2015
- CLDF Pathway to Care Campaign
 - Howard Brown Health Center Chicago IL November 24, 2015
- Simply Speaking Hepatitis CME/CE 2015 Hepatitis C Post Conference
 - Updates from AASLD December 29, 2015 Chicago IL
- 2016** GALA (GI and Liver Association of the Americas) CME series:
 - Assessing and Managing HCV Resistance, Chicago IL February 10
 - Assessing and Managing HCV Resistance, Dallas TX February 15
 - Assessing and Managing HCV Resistance, Cleveland, OH February 18
 - Assessing and Managing HCV Resistance, Detroit, MI March 21
 - Assessing and Managing HCV Resistance, Chicago IL April 5
 - Assessing and Managing HCV Resistance, Chicago IL April 21
 - Assessing and Managing HCV Resistance, New York, NY April 28
 - Assessing and Managing HCV Resistance, Chicago IL December 13
- CLDF HCV PRIME, CME Naperville, IL March 1, 2016
 - Burbank IL December 7
- Medical Grand Rounds, Presence St. Joseph Medical Center (CME)
 - Updates in Hepatitis C Joliet, IL March 2
 - Updates in Cirrhosis Joliet, IL March April 6
- CISGNA Voices in GI 2016 Spring Conference (CME) *Updates in Hepatitis C*
 - March 7 Urbana, IL
- CLDF Current and Future Treatment Options for PBC, NASH and Hepatic Encephalopathy, CME series
 - Chicago, IL May 4
 - Chicago, IL August 3
 - Oak Lawn, IL September 6
- SC Liver Research Consortia, CME: Emerging Therapies for PBC, NASH and ESLD
 - Chicago IL May 14
- GALA (GI and Liver Association of the Americas) Cleveland CME
 - Conference: Moderator and Faculty June 3
- FRESENIUS Kidney Care; Hepatitis C for Medical Directors Chicago June 8
- PRIME Education, CME: Payer and Provider Collegial Discussions to Overcome Barriers in Evidence-based Treatment of HCV and IBD,
 - Chicago IL June 14
- FSJH Grand Rounds: After the Cure (HCV) Olympia Fields IL July 22
- MacNeal Hospital Grand Rounds (Liver Failure) July 25

- ALF National Patient Advocacy Committee Meeting An update on HCV
Chicago IL July 28
- 10th University of Florida Annual GI/Liver Update A HCV Update
Clearwater Beach, FL July 29
- Grand rounds Mt. Sinai (Acute Liver Failure) Chicago IL August 3
- Hepatitis C and End stage renal disease Fresenius Kidney Care August 5
- PRIME Education, CME: Second Annual Roundtable Seminars for Federal
and Government Healthcare Clinicians Managing Patients with HCV, HIV, and
HCV-HIV Co-infection
August 13 Birmingham, AL
October 8 San Antonio TX
- CLDF HCV Advances: HCV Treatment Update for Gastroenterologists, CME
Chicago, IL September 15
Chicago IL October 13
- Hepatology Updates for West Suburban Gut Club, CME October 4
- Scripps' National Hepatitis B&C Training Program and Treatment Update
Chicago IL October 15
- CLDF CME "Triple E for HCV: Engagement, Education, and Eradication of
HCV Among Patients with Substance Use Disorders."
Will County Health Department, Joliet, IL November 4
Lake County Health Department Waukegan, IL December 15
- 2017** GALA (GI and Liver Association of the Americas) CME series:
Cleveland OH March 14
Urbana IL March 16
- 1st Annual Hepatobiliary Course Florida Hospital Nicholson Center
Tampa, FL February 24
- 2017 Emerging Therapies for PBC, NASH, ESLD & HCC CME series
Chicago IL February 25
- Practicing Clinicians Exchange (PCE) Faculty: Management of HCV
Chicago IL May 13
Washington DC May 20
- Annual Clinical Care Options Hepatitis Symposium
San Francisco CA June 10
- PRIME CME: *2nd Annual Payer and Provider Workshops in HCV and HIV:
Tackling Patient Selection, Access, and Adherence Issues* Chicago 9/13
- CLDF CME: Clinical Insights into the Management of Primary Biliary
Cholangitis (PBC)
Chicago September 26, 2017
- 2018** CLDF CME Series: Complications of Cirrhosis: Strategies to Improve Long-Term
Patient Outcomes
Mercy Health Muskegon MI January 16
Jonesboro, AR January 25
Chicago February 15
Chicago February 27
- Interpretation of liver enzymes and the role of statin therapy
Grand Rounds St James Olympia Fields February 16
- GALA (GI and Liver Association of the Americas) Regional CME conference:
Atlanta GA May 11
San Diego September 21- faculty and case moderator
- Annual Clinical Care Options Hepatitis Symposium
Lecturer and panelist: Special Populations May 19 San Francisco CA

The Impact of NAFLD in Primary Care, Kankakee IL July 11
 Clinical Viewpoints (CME): Advances in the Management of Thrombocytopenia in Chronic Liver Disease
 Chicago IL July 19
 Charlottesville, Virginia July 24
 First Annual 2018 Advanced Hepatology Educational Summit for GI Fellows CLDF
 Chicago IL August 10-11
 CLDF CME Series: HCV Advances 2018
 Community Hospital Muster IN Grand rounds August 27
 CLDF CME Series: Hepatic Encephalopathy The Pathway To Quality Care
 Lutheran General GI grand rounds August 29

National/International Presentations

- 2002** OMEN-TV: Medical education television and radio program
 Management of Cirrhosis CME Broadcast from Columbus, Ohio 2002
- 2003** National A1AT Foundation:
 A1AT Liver Disease Pathogenesis and Treatment Oak Brook, IL
- 2004** ACG October Breakfast Session: 60,000 People Can't be Wrong, CAM therapy and liver disease CME Orlando, FL
- 2006** Chicago Oak Brook, Illinois Alpha-1 Education Day: Alpha-1 Liver Disease November 11th Oak Brook, IL
- 2008** InTimeTV Internet TV talk show – *Insights in Medicine* June 27, 2008
 NAFLD update CME
 NAFLD: Non Alcoholic Fatty Liver Disease, What every GI should know. CME
 The Cedars-Sinai Medical Center 9th Annual Update in Gastroenterology
 Lake Tahoe, CA September 21
- 2009** Digestive Disease Week (DDW) 2009 Chicago, IL
 Oral Presentation: Maintenance Care of the Cirrhotic Patient
 Topic Forum Care of the Patient with Chronic Liver Disease.
 May 31, 2009
 Digestive Disease Week 2009 Chicago, IL Meet the Professor Lunch:
 HCV: Co-presenter with Donald Jensen June 1, 2009
 Digestive Disease Week 2009 Chicago, IL Meet the Professor Lunch:
 HCV and transplantation. Co-presenter with F Fred Poordad
 June 2, 2009
- 2010** HCV NOVA CME Meetings Series
 May 6: Hopes and Challenges for the Treatment-Experienced Patient
 Charlotte, NC
 May 19: On the Cusp of Change: New Therapeutic Modalities for HCV.
 Gary, IN
 May 20: On the Cusp of Change: New Therapeutic Modalities for HCV
 Kalamazoo, MI
 June 9: On the Cusp of Change: New Therapeutic Modalities for HCV.
 San Juan, PR
 Digestive Disease Week (DDW) New Orleans, LA
 Oral Presentation: Topic Forum: Hepatitis B Management May 2010
 Medscape CME/CE video roundtable discussion
 Evaluation and Initial Therapy of the HBV-Infected Patient: A Clinician Dialogue
<http://cme.medscape.com/viewarticle/732454> Released 11/30/10
 Best of the AASLD Road Show November 10-12
 An update on Hepatitis B; Kansas, Houston, Nashville

- 2011** Content and Faculty: Gastroenterology and Hepatology Review
 American Physician Institute for Advanced Professional Studies
 March 4, 2011 Las Vegas NV
 Medscape CME/CE video roundtable discussion
 Understanding Resistance in Chronic HCV Infection: Lessons Learned from HIV and HBV <http://www.medscape.org/viewarticle/754066> released 11/30/2011
 The Liver Meeting 2011: 62nd Annual Meeting of the American Association for the Study of Liver Diseases
 AASLD General Hepatology Update: Hepatic Manifestations of Gastrointestinal Diseases. November 6, 2011 San Francisco
 The Liver Meeting 2011: 62nd Annual Meeting of the American Association for the Study of Liver Diseases Co-Moderate Parallel Session, HCV: Therapeutic Horizons November 8, 2011
- 2012** The Cedars-Sinai Medical Center 13th Annual Update in Gastroenterology
 Hepatic Manifestations of GI diseases. Los Angeles, CA March 9, 2012
 HCV Pri-Med Meeting Series, Content Development and Faculty
 Ft. Lauderdale, FL February 9, 2012
 Anaheim CA April 11, 2012
 New York, NY June 22, 2012
 Chicago IL September 2012
 San Francisco CA October, 2012
 Video CME Summit: Opening a New Chapter in HCV: Focus on the Achievement of Successful Treatment Outcomes with HCV Protease Inhibitor Therapy Maximizing Success and Minimizing Risks: The Role of IL28B Testing and Hepatitis C Viral Kinetics May 17, 2012
 DAA Treatment: A Guide for Managing the HCV Epidemic A Free Live CME/CE Satellite Symposium. Presented at DDW May 20, 2012
 Clinical Care Options 2012 Annual CCO HIV and Hepatitis C Symposium
 DAA in Current Practice: A Primer for the Practitioner
 June 8-11, 2012 Hollywood Florida, Faculty
 Vertex Therapeutic Specialists and Treatment Educators, HCV
 June 20 Carlsbad CA
 Faculty Educator
 Vertex Primary Care Webcast, HCV Infection in the Primary Care Setting
 October 25
 Midwest Clinicians' Network, Inc. CME Webinar, Diagnosis and Management of Patients with Hepatitis B October 12
 Kadmon AASLD 2012 CME Event, "To Treat or Not to Treat" Faculty November 9
 Facilitate: International Hepatitis Education Program (IHEP), Faculty Presentation and Slide development at AASLD November 9-13
 2nd Global Workshop on HCV Therapy Advances
 New Antivirals in Clinical Practice in Rome, Italy, Case Moderation
- 2013** TMC435 Virtual Preceptorship Interview January 16
 Quest Hepatitis Educational Initiatives Webinar: HCV February 23
 CASL (Canadian Association for the Study of the Liver) National Nurses CME/CE Symposium
 HCV Management, Faculty and case moderation March 1
 2013 American Conference for the Treatment of HIV (ACTHIV) invited lecture "Future HCV Therapies" Denver, CO March 21-23
 Digestive Disease Week (DDW) Focused Clinical Update "Liver Disease in Pregnancy" May 20, 2013 Orlando FL

- American Medical Forum CME conference, Hepatitis Update Chicago IL
 AASLD Act-First Curriculum
 ACT-First Hepatitis C- Sub-Module 2: Patient with new diagnosis of HCV
 2013 *American Physician Institute for Advanced Professional Studies*,
 CME- accredited board preparation course.
 September 2013 Chicago IL
 Inaugural Fall IAS–USA: CME
 The Next Wave of Interferon Alfa-Containing Treatments October 2013 Chicago IL
 <https://www.iasusa.org>
 Invited Session: The Liver Meeting 2013 AASLD Postgraduate Course
 Current Status and Benefits of Therapy for Chronic Hepatitis C November
 Washington DC
 Moderator, The Liver Meeting 2013 AASLD HCV Symposium
 November Washington DC
2014 Pri-Med Annual CME Series, Content Development and Faculty:
 Viral Hepatitis
 February 2014, Ft Lauderdale FL
 March 2014, Anaheim CA
 September 2014, Boston MA
 ACT-on-HCV teleconference January 2014 AASLD sponsored educational
 Program
 Invited Session: Digestive Disease Week (DDW) Post-Graduate Course
 Clinical Challenge Session: The Cirrhotic Patient with HCV: Avoiding
 Potential Pitfalls (presenting with Jordan Feld)
 Projects in Knowledge, CME Symposium
 Hepatitis C, Treatment Goes Viral May 2
 Invited Session: Digestive Disease Week (DDW)
 Breakfast with the Expert: Treatment of Hepatitis C:
 Use of Newly Approved Drugs
 Moderator, DDW 2014
 Session: Hepatitis C Treatment: Using the Tools We Have Today
 Invited Session: Digestive Disease Week (DDW)
 Clinical Symposium: Keeping Up With Changes in HCV Therapy
 IFN Free Phase 2/3 Results: What the Future Holds
 ACTHIV 2014: Speaker and Panel Discussion
 Current State of Treatment for HCV Denver, CO May 9
 CLDF and Focus Medical Communications: Webinar
 Current Perspectives into the Management of Hepatic Encephalopathy July 12,
 2014
 Invited Presentation: 2014 Accordant Client Summit
 The changing paradigm of HCV treatment, Greensboro NC Sept 16
 2014 AMCP (Academy of Managed Care Pharmacy) Nexus Meeting
 CME Symposium Clinical Faculty Capitalizing on HCV Advancements:
 Treatment Management and Benefit Design Strategies for Managed Care.
 October 10 Boston, MA
 Hepatitis C: Treatments, Access, and a Call to Action; Webinar hosted by the
 Digestive Disease National Coalition November 5, 2014
 CCO (Clinical Care Options) Live Satellite Symposium (CME) ‘*The Waiting Is
 Over: The Era of All-Oral HCV Therapy Starts Now*’ November during the
 2014 AASLD Liver Meeting in Boston MA
 Vindico Medical Education Symposium (CME) ‘*Assessing Real-World*

- Outcomes with New HCV Regimens in 2014: HCV-TARGET Registry Findings* November 10, 2014 at the AASLD Liver Meeting
- Quest Diagnostics CME Webinar LIVE: November 17, 2014
- An Update on Hepatitis C: Diagnosis, Management and Therapy
- Fourth HCV Therapy Advances Workshop – New Antivirals in Clinical Practice. Moderator and Speaker What Is the Optimized Treatment Duration? To Overtreat versus Undertreat. Paris France 12/12/14
- 2015** Optimal Management of HIV Disease & Hepatitis: Clinical Conference XXIII (OPMAN) Faculty: Monitoring the HCV Patient-Before and After Therapy Miami FL March 27-29
- American Conference for the Treatment of HIV (ACTHIV) 2015: CME Speaker and Panel Discussion
- Fundamentals in the Care of People with Hepatitis B and C Co-infection Dallas, TX April 30
- Invited Speaker: Digestive Disease Week (DDW) 2015 Washington DC
- Clinical Symposium: Hepatitis C Treatment Recommendations for 2015 Current Regimens and Indications
- Invited Speaker: Digestive Disease Week (DDW) 2015 Washington DC
- Clinical Symposium: How Far Do We Go to Eradicate Hepatitis C? Cost Effectiveness of Hepatitis C Treatment
- Invited Speaker: Digestive Disease Week (DDW) 2015 Washington DC
- State-of-the-Art Lecture
- Issues in Hepatitis C: Identification, Access to Care, and Cost
- Digestive Disease Week (DDW) 2015 Dinner Symposium (CME) Faculty
- Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV
- Invited Speaker: 2015 ID Week Managing Hepatitis Symposium, San Diego CA
- Diagnosing and Managing Advanced Liver Disease October 2015
- Invited Speaker: 2015 ACG (American College of Gastroenterology)
- Hepatitis Symposium: New Guideline Based Treatment
- Honolulu Hawaii October 2015
- Activity Chair: AASLD CME symposium and AASLD enduring titled, **“Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV – Interact with HCV Experts on Patient Cases.”**
- Faculty: AASLD CME symposium and AASLD enduring titled, **“Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV – Interact with HCV Experts on Patient Cases.”**
- Invited Speaker: **Yale Liver Update 2015 CME** December 4, 2015 New Haven, CT
- “Special Populations in HCV therapy”
- Gilead Sciences HCV MAAP (Medical Affairs Advisory Program): HCV Screening and Linkage to Care; Foster City December 16-17
- Debate with Natasha Martin: HCV can be eliminated (PRO)
- 2016** The International Association of Providers of AIDS Care (IAPAC), 5th International Conference on Viral Hepatitis; Keynote Speaker: After the Cure: Looking Ahead in HCV Management San Francisco CA March 14
- Panel participant, EASL HCV Guidelines Workshop International Liver Congress 2016 -51st annual meeting of the European Association for the Study of the Liver. April 2016, Barcelona Spain.
- Activity Chair: DDW CME symposium and DDW enduring titled, “HCV Updates and Case Challenges for the Rapidly Changing Landscape.” San Diego 5/21
- AASLD Moderator: DDW 2016; Topic Forum, Hepatitis C: Existing and Developing

- Therapy San Diego CA, May 23
- Invited Speaker: DDW 2016 Session: Prospects for New HCV Treatments San Diego
- Invited Speaker: DDW 2016 Session: AGA POSTGRADUATE COURSE
LUNCHEON BREAKOUT SESSION: Hepatitis C: Update on the Treatment Guidelines San Diego CA May 21
- Invited Speaker: “Resistance in HCV: From clinical Trial to Real World Evidence”
Infectious Disease Grand Rounds
Geneva, Switzerland September 21
- Invited Speaker: “Resistance in HCV: From clinical Trial to Real World Evidence”
Swiss Society of Gastroenterology Annual Meeting 2016
Interlaken, Switzerland September 22
- Global HCV forum, Real World Data
Athens Greece October 25
- Invited Speaker: “Vaccination and Liver Disease”
Gastro 2016| EGHS-WGO International Congress
Abu Dhabi, UAE November 21
- Invited Speaker: “HCV: From clinical Trial to Real World Evidence”
Gastro 2016| EGHS-WGO International Congress
Abu Dhabi, UAE November 22
- Invited Speaker: 2016 AASLD (American Association Study of Liver Disease)
Early Morning Workshop 09: *Hepatitis C Treatment Duration: How Short Can It Be?* Sunday, November 13, 6:45 am – 7:45 am
- Invited Speaker: 2016 AASLD (American Association Study of Liver Disease)
HCV SIG symposium entitled: *Hepatitis C: Treatment Challenges in the DAA Era, Pan-genotypic Therapy* November 14 Boston MA
- Activity Chair: CCO AASLD CME symposium and AASLD enduring titled,
“Addressing Practical Challenges in HCV Management.” November 14
- Invited Speaker: AASLD Post Congress Debrief November 15 Boston MA
HCV Real World Data
- Gilead Sciences HCV MAAP (Medical Affairs Advisory Program):
HCV Elimination; Foster City December 8-9
The Current Status of HCV Infection in the United States
- Invited Speaker: HepCure Webinar: HCV: After The Cure 12/13
- Invited Speaker for American Liver Foundation (ALF) and National Kidney Foundation (NKF) Hep C webinar December 14
- 2017** Invited Speaker: Gilead Annual National Meeting
“What is the status of HCV in the United States?” Jan 31, Dallas
- Invited Speaker: Belgian Week for Gastroenterology MSD Symposium
“Crossing the final line: Achieving cure in Hepatitis C for all” February 8 Antwerp
- Faculty GUILD 2017 GI Update in IBD and Liver Disease Maui February
- How I Do It:** HCV Management After Cure: Transferring care back to the PCP
- How I Do It:** HCV treatment in patients with compensated and decompensated cirrhosis
- Invited Speaker: HepCure Webinar: Institute for Advanced Medicine Mount Sinai
HCV Treatment Failures March 7
- Invited Speaker: Romanian Society of Gastroenterology and Hepatology (SRGH)
Update on Hepatology 2017 Bucharest April 6-7
Session Moderator and lecturer: Extrahepatic manifestations of HCV
- EASL Symposium: MSD “What we learned from the real world” April 21
Amsterdam

- HCV treatment in decompensated cirrhosis, DDW/ALF symposium May 5
 Invited Speaker: Intercept Medical Science Liaison Meeting at DDW May 9
 Wako panelist, Enhanced HCC Surveillance at DDW May 8
 Simply Speaking Hepatitis, Clinical Clips CME at DDW
 5/7, 5/8, 5/9 and Live Wrap up 5/16
 18th International Workshop on Clinical Pharmacology of Antiviral Therapy
 Debate: Do we need more HCV therapy PRO vs. Chicago IL June 14
 Invited Speaker: International AIDS Conference (IAS 2017) MSD Symposium
 Striving Towards HCV Elimination: From Key Learning to Clinical Practice
 Clinical Trials Learning Translated to Real World Data July 23 Paris France
 Invited Speaker: 2017 Annual Meeting of the National Hemophilia Foundation (NHF)
 Taking Action to Eliminate Hepatitis C in Patients with Hemophilia and Other
 Bleeding Disorders Chicago IL August 25 [CME]
 Invited Speaker: 12th International Meeting on Therapy in Liver Diseases
 MSD Symposium Barcelona Spain September 20
 Expanding the horizons in Hepatitis C treatment: from patient cure to public health
 impact
 International Hepatology Summit (IHS) Faculty HCV and HBV Dubai, UAE October
 Clinical Benefit of SVR in Early Disease
 Pan-Genotypic Case Studies
 Management of NA-Experienced patients and HBV Resistance
 HBV Resistance Case Studies
 6th International Conference on Viral Hepatitis (ICVH) Chicago IL October 8-9
 Course Co-Chair and Lecturer
 Clinical Care Options' (CCO) *Viral Hepatitis Alerts* Web based program
 How Recent Drug Approvals Affect First-line HCV Treatment
 The Impact of New Options for Treatment-Experienced Patients with HCV
 Invited Speaker: ACG/WGO Session Moderator and Lecturer
 Breakfast Session P: Advances in the Management of Cirrhosis and Portal
 Hypertension
- 2018** Simply Speaking Hepatitis (CME) Educator Training workshop January 26-27, New Orleans
 Invited Speaker: 30th Belgian Week of Gastroenterology, Symposium February 22
 Beyond the efficacy of HCV treatments, what does really matter? A pros and cons
 debate
 Postgraduate Institute for Medicine and Clinical Care Options, Key Viral Hepatitis Studies
 Influencing My Practice Following EASL 2018 CME WebEx
 Invited Speaker: Romanian Society of Gastroenterology and Hepatology (SRGH)
 5th UpDate on Hepatology 2018 Bucharest April 26-27
 Invited Speaker: European Virology Meeting HIV and HCV: From Clinical Trials to Real
 World Data- Too Soon to Rest? Lisbon, Portugal April 27-28
 AASLD Clinical Hepatology Update 2018, Austin TX May 5
 The Adult Survivor of Pediatric Liver Disease
 DDW 2018 Clinical Symposium Liver Disease in Pregnancy June 5, Washington DC
 Treatment of Viral Hepatitis During Pregnancy
 ACG Hepatology Circle Webinar: "Difficult Cases of NASH: The Experts Discuss"
 Moderator June 12
 ACG Hepatology Circle Webinar: "Case Studies in HCC and Screening: The Experts
 Discuss" Panelist June 20
 Invited Speaker: MSD Satellite Symposium at the XIV International Symposium on Viral
 Hepatitis and Liver Diseases. "Getting on the Road: What Are We Learning from the
 Real World?" Barcelona Spain June 29

Faculty member: AASLD CME Webinar, *Implications of the Hepatitis C Epidemic on Women & Children -HCV in Women of Childbearing Age* September 7

TEACHING EXPERIENCE AND CURRICULUM DEVELOPMENT

Intramural

University of Chicago Gastroenterology Fellows

- 2005 - present Clinic Preceptorship for Rotating Liver Fellow (one clinic/week)
University of Chicago Hospitals
- 2005 - present Clinic Preceptorship for Advanced Hepatology/Transplant Liver Fellow (one clinic/week)
University of Chicago Hospitals
- 2005- present Case and Topic Discussions for Rotating Liver Fellow (one hour/day, three days/week, six weeks/year while on inpatient service)
University of Chicago Hospitals
- 2005-present University of Chicago GI fellow board review
Metabolic Liver Diseases 2005
Metabolic Liver Diseases 2006
Metabolic Liver Diseases May 4, 2007
Portopulmonary syndromes February 15, 2008
Hepatitis A/C/D/E March 7, 2008
Metabolic Liver Diseases November 2008
Portopulmonary syndromes June 2009
Hepatitis A/C/D/E September 2009
Hepatitis A/C/D/E February 2011
Portopulmonary syndromes March 25, 2011
Hepatitis A/C/D/E January 27, 2012
Portopulmonary syndromes May 4, 2012
Hepatitis A/C/D/E September 14, 2012
Portopulmonary syndromes January 25, 2013
Metabolic Liver Diseases December 2013
Hepatitis A/D/E March 2014
- 2006 – 2013 Clinic Preceptorship for Endoscopy Training (one half day/week, 23 blocks)
University of Chicago Hospitals
- 2008 Faculty Presentation at 2nd Academic Skills GI fellow retreat
Saturday, February 9, 2008

Medical Residents

- 2003-present Internal Medicine Resident Interviews
- 2003-2005 Rush-Presbyterian-St. Luke
- 2008-present University of Chicago
- 2005-present Case and Topic Discussions for Rotating Medical Resident (one hour/day, three days/week, six weeks/year while on inpatient service)
University of Chicago Hospitals
- 2007 Internal Medicine Resident Morbidity and Mortality Conference
An unusual case of hepatic iron overload. May, 2007
Hepatic Failure from VOD. December 13, 2007
- 2007 Internal Medicine Resident Board Review
Liver Disease September 20, 2007
- 2007 Internal Medicine Topics Lecture Series:
Hepatitis B Diagnosis, Natural History and Management May 7, 2007

Medical School

1997-2001	Ohio State University Medical Student Introduction to Clinical Medicine Course Instructor
1997-2001	Ohio State University Medical Student Physical Examination Skills Course Instructor
1997-2001	Ohio State University Medical Student Board Review Program Course Instructor
2001	Johns Hopkins Medical Student Physical Examination Skills Course Clinical Instructor (2 4 hour blocks)
2002	Johns Hopkins Medical Student Pathophysiology Course Course Lecturer Complications of Cirrhosis (1 hour)
2003-2005	Instructor for RUSH-Presbyterian-St. Luke's Medical Student Pathophysiology Course Complications of Cirrhosis 2003 Complications of Cirrhosis 2004 Complications of Cirrhosis 2005
2003-2005	Rush Medical Center Faculty Preceptor Techniques of Physical Examination, RUSH-Presbyterian-St. Luke's Medical School
2006–Present	Lecturer, Medical Biology 307, Clinical Pathophysiology Course, Liver Diseases Section Pritzker School of Medicine Complications of Cirrhosis
2006–Present	Medical Biology 307, Clinical Pathophysiology Course, Liver Diseases Section Pritzker School of Medicine Clinical Lab Preceptor
2007-current	University of Chicago Faculty preceptor 2 nd year medical student's "Patient's Perspectives" simulated patient modules (6 hours) University of Chicago

Ancillary Staff

University of Chicago Hepatology Nurse education series	
2005	Overview of Primary Biliary Cirrhosis Overview of Hemochromatosis
2006	Overview of Basic Immunosuppression October 4 Overview of Itching from Liver disease September 6 Overview of liver masses May 2
2007	Overview of Hepatorenal Syndrome July 18
2008	Interpretation of Liver Enzymes February 6 Overview of Coagulation March 5
2009	Hepatitis C and Liver Transplantation June Screening and management of Hepatocellular Carcinoma June Complications of chronic liver disease: Malnutrition Sept An update from AASLD November
2010	HHC an overview March

MENTORSHIP

Dates, names, projects

2006	May-June Dr. Anshu Sharma: Clinical Observer ship Inpatient service and Outpatient clinic September 28, 2006 Hepatology Preceptorship for local primary care doctors
------	--

- Management of HCV Non-Responders
 November 2006 Rohit Satoskar and Nidhi Singh:
 ALF Academic Debate, Academic Advisor
 Pro: HCV patients with minimal disease should be treated
 Won debate over NWU
 December 13, 2006 Betty Kritikos: Clinical Preceptorship
 Clinical Management of Hepatitis C
 November 2009 Arji Mufti and Archita Desai
 ALF Academic Debate, Academic Advisor
- 2007 July 2007 Pre-Medical Students University of Chicago; Chicago Academic Medical Program (CAMP) clinical program
 October-November 2007 Research Preceptor: Noura Sharabash and Nidhi Singh:
 AFP levels vary with etiology of cirrhosis
 Abstract submitted to EASL
 October 2007-current Research Preceptor: Archita Desai:
 The prevalence of refractory SBP in a tertiary care center
- 2008 American Medical Women's Association (AMWA)
 Lunch Box Series #2: Lifestyles and Experiences of Female Physicians in Specialties
 Thursday April 10, 2008 BSLC 115
 July 2008 Pre-Medical Students University of Chicago; Chicago Academic Medical Program (CAMP) clinical program
- 2009-10 Hooman Delghan, MD
 Hepatitis B: Do Practitioners follow AASLD guideline recommendations to initiate therapy? Abstract at DDW 2010 accepted for oral presentation
- 2010 Christie Choi
 Health Disparities in HCC screening recommendations in patients with chronic hepatitis B: Abstracts at AASLD
- 2010 Tara Gangadhar, M.D.
 Hepatitis B and Hepatitis C Virus, Directed Reading
 Committee on Clinical Pharmacology and Pharmacogenomics
- 2010 Greg Bernstein, MD: PSC a clinical dilemma
- 2011 October Naser Munir Gharaibeh: Clinical Observer ship
 Inpatient service and Outpatient clinic
- 2012-15 Sujit Janardhan- Clinical Continuity Fellow
- 2010 ACG Mentorship Program
 Maria Yataco MD Memphis, TN
 Jennifer Price, MD Johns Hopkins Medical Center
 Schneider, Natasha Janelle Vanderbilt.
- 2011 ACG Mentorship Program: Christine Hsu New Your Presbyterian Hospital Columbia
- 2012 ACG Mentorship Program: Malcolm Wells, University of Western Ontario
- 2013 ACG Mentorship Program: Anna Christina de la Cruz, University of Kentucky
- 2012-13 CLDF HCV Alliance Program- Community GI mentorship for HCV therapy
- 2013 AASDL Emerging Liver Scholars: Nicole Walsh mentee UC Resident
- 2013 Neha Chandan Observer ship
- 2014-15 HCV Peer-to-Peer- Community GI and PCP mentorship for HCV therapy
- 2014-15 Kemi Adebajo, MD Continuity GI fellow University of Chicago

RESEARCH

Current: Nancy Reau PI

1. ORA:16012903 HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study. (UF/UNC)
2. ORA:17021404: A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C previously treated with an NS5A Inhibitor + Sofosbuvir Therapy (UF/AbbVie)
3. ORA: 16022201 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis (GenFit)
4. ORA:16032305: A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (Shire)
5. ORA: 16062805: A multi-part, randomized, double-blind, placebo controlled study to assess the safety, tolerability and efficacy of LJN452 in patients with Primary Biliary Cirrhosis (Novartis)
6. ORA 17100401: Trio Health Retrospective and Prospective Observational Study: Real World Utilization of Oral Antivirals for HBV in Clinical Practice (Trio Health)
7. ORA 16112207: Evaluation of HBV RNA Assay and its Utility in the Management of Patients with HBV(Abbott)
8. ORA 17011607: Metagenomic Next Generation Sequencing (NGS) Technology to Explain Acute Hepatitis of Unknown Etiology (Abbott)
9. ORA 15082413: The Patient-Reported Outcomes Project of HCV-TARGET ("PROP UP") (UNC/PICORI)
10. ORA 17061602: A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of 24 Weeks of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection (Janssen)

Past:

1. Donor Alloreactive Delayed-Type Hypersensitivity as a Link to Rejection, A Search for an invitro tool. Advisor: Dr. Charles Orosz, Department of Medical Microbiology and Immunology, Ohio State University 1995-6.
2. A Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation, Multi-center Therapeutic Trial of the Safety, Immunogenicity, and Efficacy of GI-5005; an Inactivated Recombinant *Saccharomyces cerevisiae* Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in Patients with Chronic Hepatitis C Infection. P.I. Donald Jensen M.D. Co-investigator: N. Reau, MD
3. A Phase 2 Study of VX-950 in Combination with Peginterferon alfa-2a (Pegasys®), With Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Received Prior Treatment (VX05-950-104). P.I. Donald Jensen M.D. Co-investigator: N. Reau, MD
4. A Prospective, Multicenter, Open-Label, Comparative, Efficacy Study of Pegasys® plus Copegus® in Treatment-Naïve Latino Patients with Chronic Hepatitis C-Genotype 1, as Compared to Treatment-Naïve Non-Latino Caucasian Patients with Chronic Hepatitis C-Genotype 1. P.I. Smruti Mohanty M.D. Co-investigator: N. Reau, MD
5. A National Registry of Patients with Hepatocellular Carcinoma. P.I. Smruti Mohanty M.D. Co-investigator: N. Reau, MD
6. A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergen, C1FN) plus Ribavirin Administered Daily for 48 Weeks Versus Non-treatment in Hepatitis C Infected Patients Who are Nonresponders to Previous Pegylated Interferon Alfa plus Ribavirin Therapy. P.I. Helen Te M.D. Co-investigator: N. Reau, MD
7. A Phase 2b Study of Merimepodib in Combination with Pegylated Interferon Alfa-2a (Pegasys®) and Ribavirin in Subjects with Chronic Genotype 1 Hepatitis C, Non-Responsive to Prior Therapy with Pegylated Interferon Alfa and Ribavirin. P.I. Helen Te M.D. Co-investigator N.Reau, MD

8. A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Daily InterferonAlfacon-1 plus Ribavirin in Hepatitis C Infected Patients Who Failed to Achieve Virologic Response After Previous Pegylated Interferon Alfa plus Ribavirin Therapy and During at Least 24 Weeks of No Treatment P.I. Helen Te M.D. Co-investigator: N. Reau, MD
9. A Phase II, Randomized, Multicenter, Double-Blinded Study Evaluating the Safety and Tolerability of the HCV Polymerase Inhibitor Prodrug (RO4588161) When Given In Combination with Pegasys® With or Without Copegus® Versus the Currently Approved Combination of Pegasys and Copegus in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection. P.I. Donald Jensen M.D. Co-investigator: N. Reau, MD
10. Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by sustained virological response) and Safety of 360 mcg Induction Dosing of Pegasys in combination with Higher Copegus Doses in Treatment Naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Weight Greater than or Equal to 85 kg. P.I. Donald Jensen M.D. Co-investigator: N. Reau, MD
11. Protocol RNA003142-302 Randomized, Double-blind, multicenter study to compare the safety and efficacy of viramidine to ribavirin in treatment-naïve patients with chronic hepatitis C. PI: H. Te, M.D. Co-investigator: N. Reau, M.D.
12. A Study to Describe the Antiviral Effect of Entecavir (ETV) in Blacks/African Americans and Hispanics with Chronic Hepatitis B Virus (HBV) Infection who are Nucleoside/tide-Naïve (Protocol AI463085). PI: Smruti Mohanty, M.D. Co-investigator: N. Reau, M.D.
13. A Phase 3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Albumin interferon alfa-2b (alb-IFN) in combination with Ribavirin compared with Peginterferon Alfa-2a (Pegasys or PEG-IFN2a) in combination with Ribavirin in interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 2 or 3.Achieve-2/3. PI: K. Gautham Reddy, M.D. Co-investigator: N. Reau, M.D.
14. A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients with Genotype 1 Hepatitis C. PI: K. Gautham Reddy, M.D. Co-investigator: N.Reau, M.D.
15. A phase 2, randomized, open-label study of the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa-2b (PEG-Intron) plus ribavirin (REBETOL) versus PEG-Intron plus REBETOL in subjects with hepatitis C virus genotype 1 infection. (Protocol Number: 3173A1-200-US). PI: Helen Te, M.D. Co-investigator: N. Reau, M.D.
16. A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon α -2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response with a Prior Course of Interferon-Based Therapy (VX06-950-106). PI: Helen Te, M.D. Co-investigator: N. Reau, M.D.
17. Comparison of different treatment regimens in patients with Stage 1-2 Type C Hepatic Encephalopathy: AST-120 vs. Lactulose (AST015-00). PI: Gautham Reddy, MD. Co-investigator: N. Reau
18. A randomized, double-blind, double-dummy study to assess the efficacy and safety of prophylactic use of maribavir versus oral ganciclovir for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants. PI: Kenneth Pursell, MD. Co-Investigator: N. Reau
19. ML18179 A prospective, multi-center, open-label, comparative, efficacy study of Pegasys plus Copegus in treatment naïve Latino subjects with chronic hepatitis C genotype 1, as compared to treatment naïve non-Latino Caucasian subjects with chronic hepatitis C genotype 1 (Rush ORA 04082302) P.I. Donald Jensen M.D. Co-investigator: N. Reau, MD
20. RNA 003142-301 Randomized, double-blind, multicenter study to compare the safety and efficacy of viramidine to ribavirin in treatment naïve patients with chronic hepatitis C. (Rush ORA) P.I. Donald Jensen M.D. Co-investigator: N. Reau, MD
21. GILF 001 A phase II, double-blind, randomized, placebo-controlled, multicenter study of the safety and anti-fibrotic efficacy of interferon gamma 1b in patients with severe liver fibrosis or compensated cirrhosis due to hepatitis C. (Rush ORA 02022006) P.I. Donald Jensen M.D. Co-investigator: N. Reau, MD

22. MV17150 A randomized, open label, multi-center, efficacy and safety study examining the effects of duration of treatment and of a high induction dose of Pegasys in combination with daily Copegus in patients with chronic hepatitis C who did not respond to previous Peginterferon alfa-2b/ribavirin combination therapy (Rush ORA 03041404) P.I. Donald Jensen M.D. Co-investigator: N. Reau, MD
23. NV17318 Randomized, multicenter, double-blind, Phase IV pilot study evaluating the effect of Pegasys doses of 180 mcg or 270 mcg in combination with Copegus doses of 1200 mg or 1600 mg on viral kinetics, virological response, pharmacokinetics, and safety in interferon-naïve patients with chronic hepatitis C genotype 1 virus infection of high viral titer and body weight greater than 85 kg. (Rush ORA 03092601) P.I. Donald Jensen M.D. Co-investigator: N. Reau, MD
24. A Multicenter Screening Protocol to Assess Patients with Chronic Hepatitis C Virus infection (CHC) for Eligibility to Participate in Upcoming Studies that will Compare the Efficacy and Safety of the Combination of Pegylated Interferon alfa-2a (Pegasys®) and Levovirin (Ro 28-2768) with the Combination of Pegylated Interferon alfa-2a (Pegasys®) and Ribavirin” (Rush ORA 03021904) P.I. Donald Jensen M.D. Co-investigator: N. Reau, MD
25. CV 123246, “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Determine the Efficacy and Safety of Pravastatin 80mg Administered Once Daily to Hypercholesterolemic Subjects with Chronic, Well Compensated Liver Disease” (Rush ORA 02111901) PI: N. Reau
26. A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS® or PEG-IFN α 2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 1 (Achieve 1). PI: Nancy Reau, M.D.
27. Comparison of Weight-based Doses of Taribavirin Combined with Peginterferon Alfa-2b Versus Ribavirin Combined With Peginterferon Alfa-2b in Therapy-naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection (Protocol Number: RNA003142-204). PI: Nancy Reau, M.D.
28. Hepatitis Awareness and Prevalence among Indian and Pakistani Chicago Americans. PI: Nancy Reau, MD
29. Gilead GS-US-228-0101 NASH study: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults with Non-Alcoholic Steatohepatitis (NASH) PI: Nancy Reau, MD
30. 16290A, “Evaluation of Early Null-response (eNR) to Pegylated Interferon and Ribavirin as a Predictor of Therapeutic Nonresponse in Patients Undergoing Treatment for Chronic Hepatitis C” PI: Nancy Reau, MD
31. A clinical and pathological correlate of an elevated alpha-fetoprotein (AFP) level, independent of hepatocellular carcinoma, in patients with cirrhosis. (Protocol Number: 15848B) PI: Nancy Reau, MD
32. Is the incidence of drug resistant SBP increasing? A case series and literature review. (Protocol Number: 15713A) PI: Nancy Reau, MD Co-PI Archita Desai
33. IRB#: 10-718-A: Assessment of Quality of Care Provided to Liver Patients By Hospitalists: PI: Nancy Reau, MD Co-PI Archita Desai
34. 09-212-B, Undertreatment of Patients with Chronic Hepatitis B Based on Current Guidelines. PI: Nancy Reau, MD
35. IRB #:12-0160 Study Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Compare the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, Ribavirin) to Triple Therapy (with VX-222-Placebo) in Subjects With Genotype 1 Chronic Hepatitis C With Compensated Cirrhosis (VX11-222-106) PI: Nancy Reau
36. IRB #:11-0219: Gilead Sciences GS-US-174-0149 : A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon α -2a (Pegasys®) versus Standard of Care Tenofovir isoproxil Fumarate Monotherapy or Peginterferon α -2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects with HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB). (GS-US-174-0149)

PI: Nancy Reau, MD

37. IRB #:11-0267: GS-US-248-0120, "A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tego buvir and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Genotype 1 HCV Infection" PI: Nancy Reau, MD
38. IRB11-0642: An exploratory Phase IIa, randomized, open-label trial to investigate the efficacy and safety of 12 weeks or 24 weeks of TMC435 in combination with PSI-7977 with or without ribavirin in chronic hepatitis C genotype 1-infected prior null responders to peginterferon/ribavirin therapy (TMC435HPC2002)
39. IRB12-1024 An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α 2a and Ribavirin (pegIFN/RBV) in Genotype-1 Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous Abbott DAA Combination Study (M13-101)
40. IRB12-1159 A Phase 3, Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who are Null or Partial Responders to Peginterferon Alfa-2a or 2b Plus Ribavirin with Chronic Hepatitis C Genotypes 1 or 4 Infection (AI447-029)
41. IRB12-1242 A Randomized, Open-Label, Multicenter Study of the Safety, Efficacy, and Tolerability of Combination Treatment of Setrobuvir, Danoprevir, Ritonavir, and Copegus? with or without Mericitabine in HCV Genotype 1? Infected Patients Who are Either Treatment Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment (NP28266 Annpurna)
42. IRB12-2037 Study Title: A Randomized, Openlabel Study to Evaluate the Safety and Efficacy of ABT450/Ritonavir/ABT267 (ABT450/r/ ABT 267) and ABT333 Coadministered with Ribavirin (RBV) in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Human Cirrhosis (TURQUOISEII) PI: Nancy Reau
43. IRB10-389-A : Evaluation of HCC through a protein signature PI: Nancy Reau, MD
44. IRB14-0849: Hyperion HPN-100-022 An Observational Study to Assess Documentation of Hepatic Encephalopathy in Clinical Practice
45. IRB11-0219: Liver Clinical Registry: IRB 16291A Protocol Number: 11-0219 PI: Nancy Reau
46. IRB10-327-B A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis C infection (CHC)
47. IRB11-0139 A phase III, randomized, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 24 weeks and BI 201335 240 mg for 12 weeks in combination with pegylated interferon- α and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C infection (1220.47)
48. IRB11-0512: A phase III, randomized, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon- α and ribavirin in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN/RBV treatment (1220.7)
49. IRB11-0617: A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon- α (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN/RBV treatment (1220.48)
50. IRB12-1024 An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α 2a and Ribavirin (pegIFN/RBV) in Genotype-1 Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous Abbott DAA Combination Study (M13-101)
51. IRB12-1159 A Phase 3, Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who are Null or Partial Responders to Peginterferon Alfa-2a or 2b Plus Ribavirin with Chronic Hepatitis C Genotypes 1 or 4

- Infection (AI447-029)
52. IRB12-1837 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ ABT 267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatment-Experienced Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
 53. IRB13-1141 A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection (M13-102)
 54. IRB13-1271 A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects with Genotype 1 Chronic Hepatitis C (AI443-102)
 55. IRB13-1273 A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis (AI443-113)
 56. IRB14-1205: Evaluation of the chronic hepatitis C virus (HCV) screening rates between the Emergency Department and Medical specialties in a single center.
 57. IRB 12-0108: HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network, A Longitudinal, Observational Study PI: Nancy Reau
 58. IRB14-0949: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infection (GS-US-342-1139)
 59. IRB12-1905-CR002: Center for Translation Research of the Liver (CTRL) Chronic Liver Disease Translational Database
 60. IRB11-0302 A prospective 3-year follow-up study in subjects previously treated in a Phase IIb or Phase III study with a TMC435-containing regimen for the treatment of hepatitis C virus (HCV) infection (TMC435HPC3002)
 61. IRB14-1561: A Phase 2, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Non-Genotype 1 HCV Infection (GS-US-367-1169)
 62. IRB14-1560: A Phase 2, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Genotype 1 HCV Infection (GS-US-367-1168)
 63. IRB14-0629: AbbVie TOPAZ II: An Open-Label, Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (M14-222)
 64. IRB11-0615: A Long Term Follow-up Registry for Subjects Who Did Not Achieve a Sustained Virologic Response To Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection (GS-US-248-0123)
 65. IRB11-0616: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response To Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection (GS-US-248-0122)
 66. A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients with Chronic Hepatitis C Virus Genotype 1 – 6 Infection (MAGELLAN-2) (M13-596)
 67. ORA 15100105: 707-207 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Finding, Clinical trial Evaluating the Efficacy and Safety of Obetocholic Acid in Subjects with Primary Sclerosing Cholangitis (ASEOP) (Intercept Pharmaceuticals)

PUBLICATIONS (in chronological order)

Peer-reviewed:

1. **Reau NS**, Senturia YD, LeBailly SA, Christoffel KK. Infant and Toddler Feeding Patterns and Problems: Normative Data and a New Direction. *Journal of Developmental and Behavioral Pediatrics*. 17(3):149-53, 1996 June
2. **Reau NS**, Young JJ, Mazzaferri EL. Abdominal Pain in a Woman with Cancer. *Hospital Practice*. Vol. 34 No. 11, October 15, 1999.
3. **Reau NS**, Kalloo AN. Sclerosing Cholangitis: Diagnosis and Management. *Techniques in Gastrointestinal Endoscopy*; July (4):147-56, 2002.
4. Sauk J, Jensen DM, Mohanty SR, **Reau N**, Reddy KG, Te HS. Lack of efficacy of pegylated interferon monotherapy for hepatitis C in patients with end-stage renal disease on dialysis. *Gastroenterol Hepatol*. 2006;2(7).
5. **Reau NS**. Best of AASLD. *Gastroenterology and Hepatology*. 2007;3:51-54
6. **Reau NS**, Jensen DM. Current Developments in the Treatment of Hepatitis B and C. *US Infectious Diseases*. 2007;1:29-30.
7. **Reau N**, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. *American Journal of Gastroenterology*. 2008; Aug;103(8):1981-8.
8. Singh N, **Reau N**. Management of Hepatitis B Virus. *The Journal of Antimicrobial Chemotherapy*. 2008; Aug;62(2):224-8.
9. Aronsohn A, **Reau N**. Long Term Outcomes after Treatment with Interferon and Ribavirin in HCV Patients. *J Clin Gastroenterol*. 2009 Aug;43(7):661-71.
10. Poordad FF, **Reau N**. Viral Guided Hepatitis C Therapy. *Current Hepatitis Reports*. 2009.8(2):66-72.
11. **Reau N**, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, Mohanty S, Jensen D. Evaluation of Early Null Response to Pegylated Interferon and Ribavirin as a Predictor of Therapeutic Nonresponse in Patients Undergoing Treatment for Chronic Hepatitis C. *The American Journal of Gastroenterology* , (9 November 2010) | doi:10.1038/ajg.2010.424
12. Mufti A, **Reau N**. IL28B: Implications for Therapy. *Current Hepatitis Reports*. 2011.10(3):152-161.
13. Desai AP, **Reau N**. Naives, nonresponders, relapsers: who is there left to treat? *Clin Liver Dis*. 2011 Aug;15(3):483-95.
14. Desai AP, **Reau N**. Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease. *Therapeutic Advances in Gastroenterology*. 2012 Sep;5(5):275-83. doi: 10.1177/1756283X11417037.
15. Marcellin P, **Reau N**, Ferencei P, Hadziyannis S, Messinger D, Tatsch F, Jensen D. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. *J Hepatol*. 2012 Feb 4. PMID: 22314423
16. **Reau N**, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. *J Viral Hepat*. 2012 Feb;19(2):94-102.
17. John N. Gaetano, Archita P. Desai, **Nancy Reau**. The Era of Direct-Acting Antivirals: The Evolving Role of Interferon and Ribavirin for the Treatment of Chronic Hepatitis C. *Clinical Medicine Insights: Therapeutics* 2012;4 39-56 doi: [10.4137/CMT.S6792](https://doi.org/10.4137/CMT.S6792)
18. Mufti, Arjmand R., **Reau N**. Liver Disease in Pregnancy. *Clin Liver Dis*. 2012 May;16(2):247-269.
19. Te HS, Dasgupta KA, Cao D, Satoskar R, Mohanty SR, **Reau N**, Millis JM, Jensen DM. Use of immune function test in monitoring immunosuppression in liver transplant recipients. *Clin Transplant*. 2012 May 3. [Epub ahead of print]
20. Desai AP, **Reau N**., Reddy KG, Te HS, Mohanty SM, Satoskar R, DeVoss A, Jensen D. Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease. *Therapeutic Advances in Gastroenterology*. 2012 Sept; 5(5): 275-83.
21. Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, **Reau NS**, Sherman K, Terrault N, Thomas D. [Hepatitis C virus: a critical appraisal of new approaches to](#)

- [therapy](#). Hepat Res Treat. 2012;2012:138302. doi: 10.1155/2012/138302. Epub 2012 Oct 8. PMID: 23094146 [PubMed] **Free PMC Article**
22. Gaetano JN, **Reau N**. [Hepatitis C: management of side effects in the era of direct-acting antivirals](#). Curr Gastroenterol Rep. 2013 Jan;15(1):305. doi: 10.1007/s11894-012-0305-1. PMID: 23269576 [PubMed - in process]
 23. Satoskar R, **Reau N**. [Potential consequences of healthcare recommendations: A focus on the USPSTF](#). Hepatology. 2013 Mar 4. doi: 10.1002/hep.26349. [Epub ahead of print] No abstract available. PMID: 23460345 [PubMed - as supplied by publisher]
 24. **Reau N**. [Finding the needle in the haystack: Predicting mortality in Pregnancy-related liver disease](#). Clin Gastroenterol Hepatol. 2013 Aug 17. doi:pii: S1542-3565(13)01199-3. 10.1016/j.cgh.2013.08.019.
 25. Desai AP, Satoskar R, Appannagari A, Reddy KG, Te HS, **Reau N**, Meltzer DO, Jensen D. [Co-Management Between Hospitalist and Hepatologist Improves the Quality of Care of Inpatients With Chronic Liver Disease](#). J Clin Gastroenterol. 2013 Oct 4. [Epub ahead of print]
 26. Recommendations for Testing, Managing, and Treating Hepatitis C; AASLD and IDSA Treatment Guideline <http://www.hcvguidelines.org>
 27. **Reau NS**, Jensen DM. Sticker Shock and the price of new therapies for hepatitis C: Is it worth it? Hepatology. 2014 Feb 3. doi: 10.1002/hep.27039. [Epub ahead of print]
 28. Aronsohn A, **Reau N**, Jensen D. [Preparing for the uncertain yet inevitable: Off-label combinations of antiviral agents in hepatitis C virus](#). Hepatology. 2014 May;59(5):1688-91. doi: 10.1002/hep.26903. Epub 2014 Mar 1. No abstract available. PMID:24806752
 29. Nancy Reau. HCV testing and linkage to care: Expanding access. Clinical Liver Disease. 2014. August; 4(2) 31-49.
 30. Sengupta S, Wroblewski K, Aronsohn A, **Reau N**, Reddy KG, Jensen D, Te H. [Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start?](#) Dig Dis Sci. 2015 Mar 6. [Epub ahead of print] PMID: 25742912
 31. Adebajo CO, Reau N. Overtreating versus undertreating: What is the optimized treatment duration in HCV?. Future Virology. 2015;10(9):1049-1056. doi:10.2217/fvl.15.71
 32. Janardhan S, **Reau NS**. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? [Hepat Med](#). 2015 Apr 16;7:11-20. doi: 10.2147/HMER.S79584. eCollection 2015. PMID: 25926761
 33. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, **Reau N**, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA - Journal of the American Medical Association. 2015;313(17):1736-1744. doi:10.1001/jama.2015.3868 PMID: 25942724
 34. Teriaky A, **Reau N**. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis. 2015 Nov;19(4):591-604. Doi:10.1016/j.cld.2015.06.001 PMID: 26466649
 35. AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA recommendation for testing, managing and treating adults infected with hepatitis C virus. Hepatology.2015; Sept;62(3):932-54. Doi:101002/hep.27950. PMID: 26111063
 36. **Reau N**, Fried MW, Nelson DR, Brown RS Jr, Everson GT, Gordon SC, Jacobson IM, Lim JK, Pockros PJ, Reddy KR, Sherman KE. HCV Council-Critical Appraisal of Data. Recommendations for Clinical Practice in a Rapidly Evolving Therapeutic Landscape. Liver Int. 2015 Oct28. Doi:10.1111/liv.12993. PMID: 26509462
 37. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, **Reau N**, Mangia A, Sulkowski M; ASTRAL-2 and ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV

- Genotype 2 and 3 Infection. *N Engl J Med*. 2015 Dec 31;373(27):2508-17. Nov 17[Epub ahead of print] PMID 26575258
38. Gaetano JN, Micic D, Aronsohn A, Reddy G, Te H, **Reau NS**, Jensen D. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. *J Gastroenterol Hepatol*. 2015 Dec 8. Doi:10.1111/jgh.13255. PMID: 26642977
 39. Reau NS, Korner EJ, Han J, Jensen D. Anemia Predicts Sustained Virological Response in Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C Treated with Peginterferon Alfa-2a and Ribavirin. *Current Hepatitis Reports*. 2015;14(1):53-59. doi:10.1007/s11901-015-0257-7
 40. Desai AP, Reau N. The Burden of Rehospitalization for Patients With Liver Cirrhosis. *Hosp Pract*. 2016 Feb 3:1-10. PMID: 26782133
 41. Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. *Am J Gastroenterol*. 2016 Feb 2. Doi: 10.1030/ajg2015.430. PMID: 26832651
 42. Shiffman ML, Rustgi V, Bennett M, Fornis X, Asselah T, Planas Vila R, Liu L, Pedrosa M, Moller J, **Reau N**. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. *Am J Gastroenterol*. 2016 Apr 5. doi: 10.1038/ajg.2016.108. [Epub ahead of print] PMID: 27045929
 43. Jensen DM, Sebhatu P, **Reau NS**. Generic medications for hepatitis C. *Liver Int*. 2016 Jul;36(7):925-8. doi: 10.1111/liv.13120. PMID: 27306302
 44. Younossi ZM, Stepanova M, Sulkowski M, Foster GR, **Reau N**, Mangia A, Patel K, Brau N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and 3 Clinical Trials. *Clin Infect Dis*. 2016 Jul 20. pii: ciw496. PMID: 27444413
 45. Lawitz E, **Reau N**, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, Younes Z, Herring R Jr, Reddy KR, Tran T, Bennett M, Nahass R, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Pearlman B, Shiffman M, Hawkins T, Curry M, Jacobson I. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with Genotype 1 Hepatitis C Virus Infection in an Open-label, Phase 2 Trial. *Gastroenterology*. 2016 Jul 30. pii: S0016-5085(16)34835-1. doi: 10.1053/j.gastro.2016.07.039. [Epub ahead of print] PMID: 27486034
 46. Mikolajczyk AE, Farnan JM, McConville JF, Jensen DM, Reddy KG, Te HS, **Reau N**, Aronsohn AI. Novel Educational Interventions in Residency Increase Knowledge of Chronic Liver Disease and Career Interest in Hepatology. *Hepatology*. 2016 Aug 10. doi: 10.1002/hep.28741. [Epub ahead of print] PMID: 27506929
 47. Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, Jacobson IM, Afdhal N, Alam I, Ben-Ari Z, Bredfeldt J, Chung RT, Harlan W, Dickson RC, Elbeshbeshy HA, Everson G, Fenkel JM, Galati J, Gordon SC, Hassan M, Hawkins TN, Hinestrosa F, Kerr CA, Kwo PY, Levitsky J, Lok AS, Mailliard M, Manns MP, Muir AJ, O'Leary JG, Pearlman BL, Pockros P, Ramani A, Reau N, Schiff ER, Sherman KE, Shiffman ML, Smith C, Spivey JR, Sterling RK, Szabo G, Terrault NA, Trautwein C, Watts K, Williams A, Zeuzem S. Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection. *Gastroenterology*. 2016;150(2):419-429. doi:10.1053/j.gastro.2015.10.013 PMID: 26497081
 48. Evon DM, Golin CE, Stewart P, Fried MW, Alston S, Reeve B, Lok AS, Sterling RK, Lim JK, **Reau N**, Sarkar S, Nelson DR, Reddy KR, Di Bisceglie AM. Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. *Contemp Clin Trials*. 2017 Jun;57:58-68. doi: 10.1016/j.cct.2017.03.013. Epub 2017 Mar 22. PMID 28342989
 49. Behara R, **Reau N**. Updates on hepatitis C virus therapy in the direct-acting antiviral era. *Curr Opin Gastroenterol*. 2017 May;33(3):115-119. doi: 10.1097/MOG.0000000000000350. PMID: 28350558
 50. **Reau N**, Nelson DR. HBV reactivation after HCV eradication: Deja Vu. *Liver Int*. 2017 Jul;37(7):1088. doi: 10.1111/liv.13358. No abstract available. PMID: 28635166

51. Reau NS. Pangenotypic regimens and the next generation hepatitis C virus therapy. *Clinical Liver Disease*. 2017;9(6):131-133. doi:10.1002/cld.635
52. Nancy Reau, Michael N. Robertson, Hwa-Ping Feng, Luzelena Caro, Wendy W. Yeh, Bach-Yen T. Nguyen, Janice Wahl, Eliav Barr, Peggy Hwang, Stephanie O. Klopfer. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection. *Hepatology Communications* First Published: 2 August 2017
53. Nancy Reau, Francis Vekeman, Eric Wu, Yanjun Bao, Yuri Sanchez Gonzalez. **Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy.** *Hepatology Communications*. First Published: 23 May 2017
54. Kanwal F, Bacon BR, Beste LA, Brill JV, Gifford AL, Gordon SC, Horberg MA, Manthey JG, Reau N, Rustgi VK, Younossi ZM. [Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group.](#) *Gastroenterology*. 2017 May;152(6):1588-1598. doi: 10.1053/j.gastro.2017.03.039. PMID: 28442121
55. Soriano V, Young B, Reau N. [Report from the International Conference on Viral Hepatitis - 2017.](#) *AIDS Rev*. 2018 Jan 25;20(1). [Epub ahead of print] PMID: 29369303
56. Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. [Resistance Analysis in Patients with Genotype 1-6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Studies.](#) *J Hepatol*. 2017 Dec 5. pii: S0168-8278(17)32476-5. doi: 10.1016/j.jhep.2017.11.032. [Epub ahead of print] PMID: 29221887
57. Evon DM, Amador J, Stewart P, Reeve BB, Lok AS, Sterling RK, Di Bisceglie AM, Reau N, Serper M, Sarkar S, Lim JK, Golin CE, Fried MW. [Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.](#) *Aliment Pharmacol Ther*. 2018 Apr;47(7):1001-1011. doi: 10.1111/apt.14531. Epub 2018 Jan 29.
58. Nancy Reau, Paul Y. Kwo, Susan Rhee, Robert S. Brown Jr., Kosh Agarwal, Peter Angus, Edward Gane, Jia-Horng Kao, Parvez S. Mantry, David Mutimer, K. Rajender Reddy, Tram T. Tran, Yiran B. Hu, Abhishek Gulati, Preethi Krishnan, Emily O. Dumas, Ariel Porcalla, Nancy S. Shulman, Wei Liu, Suvajit Samanta, Roger Trinh and Xavier Forns. **Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection** *Hepatology*. Accepted manuscript online: 19 APR 2018 12:00AM EST | DOI: 10.1002/hep.30046
59. Reau N. [Pregnancy post-liver transplantation: Can renal function quell the fear?](#) *Liver Transpl*. 2018 Apr 6. doi: 10.1002/lt.25070. [Epub ahead of print] No abstract available. PMID: 29626391

Reviews, book chapters, books, web-based materials:

1. Reau N, Poordad FF. Medscape Gastroenterology Hepatitis B Expert Column; Endpoints in HBV Clinical Trials: Can We Compare Trial Outcomes? Posted 03/10/2006
<http://cme.medscape.com/viewarticle/524788>
2. Singh N, Reau N. Extrahepatic Manifestations of HCV Infection: A Brief Review and Update. *Current Hepatitis Reports* 2006; 5(4):133-141. <http://cme.medscape.com/viewarticle/552614>
3. Reau, N. Medscape Gastroenterology Conference Coverage: [American College of Gastroenterology 2006 Annual Scientific Meeting and Postgraduate Course: Hepatitis B-What's New and What's on the Horizon?](#) Posted October 2006
4. Reau N, Poordad FF. Medscape Gastroenterology Hepatitis C Expert Column: Hepatitis C and the Effects of an Aging Population. Posted 03/06/2007
5. Reau, N. Medscape Gastroenterology Conference Coverage: [DDW 2007: Hepatitis B-What's New and What's on the Horizon?](#) Posted 05/23/07

6. Reau NS, Jensen DM: Vanishing Bile Duct Syndrome. Up to Date. 2007-current.
http://www.uptodate.com/online/content/topic.do?topicKey=hep_dis/19935&selectedTitle=1~1&source=search_result
7. Reau, N. Medscape Gastroenterology Conference Coverage: The Liver Meeting 2007: 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Evolving Issues in Viral Hepatitis. Posted 11/9/2007.
8. Reau N, Poordad FF. Medscape Gastroenterology CME series: The Burden of Disease and the Evolving Landscape in Hepatitis C Therapy. Posted 2/08.
9. Reau NS, Jensen DM. Vanishing Bile Duct Syndrome and Adult Ductopenia. Clinics in Liver Disease. 2008;12:203-217.
10. Reau NS. Medscape Gastroenterology. Hepatitis B: Advances in Screening, Diagnosis, and Clinical Management Volume 1 CME. Update on the Treatment of Hepatitis B .Literature Review. Posted February 25, 2008. <http://www.medscape.com/viewprogram/8850>
11. Reau NS. Medscape Gastroenterology. Hepatitis B: Advances in Screening, Diagnosis, and Clinical Management -- Volume 2 CME Advances in Hepatitis B: An update from EASL 2008 Release Date: May 29,2008 <http://www.medscape.com/viewarticle/575102>
12. Reau NS. Medscape Gastroenterology. Digestive Disease Week (DDW) 2008 Hepatitis C: New Clinical Insights Posted 05/22/2008 <http://www.medscape.com/viewarticle/573933>
13. Reau NS. Medscape Gastroenterology. Hepatitis B: Advances in Screening, Diagnosis, and Clinical Management -- Volume 3 CME The role of Monotherapy vs Combination Therapy for Chronic Hepatitis B. August 2008. <http://www.medscape.com/viewarticle/579595>
14. Reau NS. A MEDSCAPE CME SPECIAL REPORT Hepatitis B: Advances in Screening, Diagnosis, and Clinical Management -- Volume 4. Advances in Hepatitis B: An Update From AASLD 2008. Posted 11/24/08. <http://www.medscape.com/viewarticle/583706>
15. Reau N, Davis G. Medscape CME HCV Case Challenges: Managing Host Factors to Optimize Outcomes Posted June 2009
http://cme.medscape.com/qna/preformservlet?questionnaireid=15461&formid=3&dest_url=http://cme.medscape.com/viewarticle/703352
16. Reau N. Medscape CME Gastroenterology: The Hepatitis C Virus: Prospecting for Specifically Targeted Therapies <http://cme.medscape.com/viewarticle/709545>
17. Reau N. CCO (Clinical Care Options) Journal Options. Defining the Incidence and Risk Factors for Hepatocellular Carcinoma in the Setting of HCV Infection. Posted April 29,2009
http://www.clinicaloptions.com/Hepatitis/Journal%20Options/Articles/Lok_Gastroenterol_2009/Commentary.aspx
18. Nancy S. Reau, MD; Adam B. Cochrane, BSPharm, PharmD “**The Evolving Therapeutic Landscape in HCV Infection -- Underlying Mechanisms and Potential New Drug Targets,**” MedscapeCME. 08/11/2010 <http://cme.medscape.com/viewarticle/726382>
19. Aronsohn, A , Mufti A, and Reau N “Does a Sustained Virologic Response at week 72 Indicate a Cure in Chronic Hepatitis C Virus?” p 73-80 Controversies in Hepatology: The Experts Analyze Both Sides Ed Donald Jensen, SLACK Incorporated, Thorofare NJ 2011
20. Steven L. Flamm, MD; Jeffrey Burack, MD, MPP, BPhil; Nancy Reau, MD. Medscape Education Infectious Diseases. Understanding Resistance in Chronic HCV Infection: Lessons Learned From HIV and HBV Medscape Education, November 2011. CME Released: 11/30/2011; Valid for credit through 11/30/2012 <http://www.medscape.org/viewarticle/754066>
21. Nancy S. Reau, MD. Medscape Infectious Diseases test and teach entitled, After the Diagnosis: Next Steps in the Care of the Patient with Chronic HBV Infection CME Released: 06/26/2012
<http://www.medscape.org/viewarticle/763115>
22. Andrew I. Aronsohn, MD; Eric J. Lawitz, MD; Fred Poordad, MD; Nancy S. Reau, MD. Medscape Education Infectious Diseases. New Treatments, New Challenges: Managing Side Effects of Treatment of Chronic HCV Infection CME/CE Released: 11/09/2012; Valid for credit through 11/09/2013 <http://www.medscape.org/viewprogram/32632>

23. Nancy S. Reau, MD; Fred Poordad, MD Medscape Education Infectious Diseases. Part 1. Managing HCV Treatment-Related Anemia CME/CE. Released 11/9/2012. <http://www.medscape.org/viewarticle/772088>
24. Reau N, Poordad FF. Primary liver cancer: Surveillance, diagnosis and treatment. Primary Liver Cancer: Surveillance, Diagnosis and Treatment. 2012;1-295. doi:10.1007/978-1-61779-863-4
25. Nancy Reau, MD: Making the Most of the Clinical Encounter: Screening for HBV From Medscape Education Family Medicine. CME released 5/29/2013
26. HepReader: The Impact of Direct-Acting Antiviral Agents in HCV CME online monograph supported by Imedex Released January 17, 2014
27. AASLD 2013 Clinical Care Options (CCO) coverage
28. "Treatment of Hepatitis C Infection: Interpreting the Latest Data from AASLD (The Liver Meeting) 2013" CME on-line activity ASiM8
29. ACP Smart Medicine, Non-Alcoholic Fatty Liver Disease Author 8/28/2014 <http://smartmedicine.acponline.org/content.aspx?gbosId=50&resultClick=3&ClientActionType=SQLR%20Direct%20to%20Content&ClientActionData=Module%20link%20Click>
30. Healio Infection Disease On-Line CME Monograph: HCV Consults: Volume 1, Number 2 http://www.healio.com/infectious-disease/education-lab/2014/05_may/hcv-consults-volume-1-number-2.
31. 2014: Clinical Care Options (CCO) Hepatitis CME: Clinical Focus: Clinical Outcomes and Cost-Benefit Considerations in HCV Therapy. Faculty http://www.clinicaloptions.com/Hepatitis/Treatment%20Updates/HCV%20Cost%20Benefit/Module/HCV_Cost_Benefit_Module.aspx
32. 2014: National Jewish Health and PVI, PeerView Institute for Medical Education CME activity, "Is Warehousing Over? Exploring Recent Developments in Direct-Acting Antiviral Therapy for HCV". Faculty www.peerviewpress.com/r336.
33. HCV Council™ 2014 Recap - Critical Appraisal of Data: Recommendations for Clinical Practice in a Rapidly Evolving Therapeutic Landscape CME Medscape Gastroenterology Michael W. Fried, MD, Course Chair; Nancy Reau, MD; David R. Nelson, MD CME Released: 09/23/2014 ; Valid for credit through 09/23/2015 <http://www.medscape.org/viewarticle/830897>
34. 2014 HCV Council 2014 Revisited at AASLD - Critical Appraisal of Data: Recommendations for Clinical Practice in a Rapidly Evolving Therapeutic Landscape. Authors(s) Faculty: Michael W. Fried, MD, David R. Nelson; Nancy Reau, MD. Released 12/13/15 CME [\[http://www.healio.com/gastroenterology/education-lab/2014/12_december/hcv-council-2014-revisited-at-aasld/cme-info\]](http://www.healio.com/gastroenterology/education-lab/2014/12_december/hcv-council-2014-revisited-at-aasld/cme-info)
35. 2014 HCV Hyperguide: Vindico CME Author: Nancy Reau
Use of All Oral Therapies: Expert Curbside Consults
http://www.hcv.hyperguides.com/initial-treatment-starting-therapy/2014/09_september/use-of-all-oral-therapies/cme-info
Management of a Genotype 1a Patient with Relatively Mild Disease
Expert Curbside Consults
http://www.hcv.hyperguides.com/initial-treatment-starting-therapy/2014/09_september/management-of-a-genotype-1a-patient-with-relatively-mild-disease/cme-info
Post Therapy SVR Monitoring Expert Curbside Consults
http://www.hcv.hyperguides.com/monitoring-patients/2014/09_september/post-therapy-svr-monitoring/cme-info
Pretreatment Evaluation of a Treatment-naïve Patient Expert Curbside Consults
http://www.hcv.hyperguides.com/initial-treatment-starting-therapy/2014/09_september/pretreatment-evaluation-of-a-treatment-naive-patienthyperguide-

[activity/cme-info](#)

Who and When to Treat: Guideline Review Slides/Audio

http://www.hcv.hyperguides.com/initial-treatment-starting-therapy/2014/10_october/who-and-when-to-treat-guidelines-review/cme-info

Hyperguide: Extrahepatic Manifestations of HCV

http://www.hcv.hyperguides.com/extrahepatic-manifestations-beyond-the-liver/2015/01_january/extrahepatic-manifestations-of-hcv/cme-info

HCV Treatment Recommendations from AASLD/IDSA/IAS–USA

http://www.hcv.hyperguides.com/initial-treatment-starting-therapy/2015/03_march/hcv-treatment-recommendations-from-aasld-idsa-ias-usa/cme-info

36. Assessing Real-world Outcomes With New HCV Regimens in 2014: HCV-TARGET Registry Findings **CME** Medscape Gastroenterology. David R. Nelson, MD, Chair; Ira M. Jacobson, MD; Nancy Reau, MD; Mark S. Sulkowski, MD CME Released: 01/22/2015 ; Valid for credit through 01/22/2016 www.medscape.org/viewarticle/831472
37. Clinical Thought: Clinical Care Options (CCO) Prioritizing Patients for HCV Therapy: The Case for Treating Before Advanced Disease Faculty Nancy Reau, MD
<http://www.clinicaloptions.com/login.aspx?item=%2fh hepatitis%2ftreatment+updates%2fhcv+cost+benefit%2fclinical+thought%2fct+1&user=extranet%5cAnonymous&site=website&q=>
38. Highlights from AASLD 2014: HCV Management Source: Official Conference Coverage 2014 Annual Meeting of the American Association for the Study of Liver Diseases CME Faculty: Michael Fried, David Nelson, Nancy Reau. Released January 14, 2015
<http://www.clinicaloptions.com/Hepatitis/Conference%20Coverage/AASLD%202014/HCV%20Management/Expert%20Analysis.aspx>
39. Current AASLD/IDSA Recommendations for Hepatitis C Antiviral Therapy in Treatment-Naïve, Noncirrhotic Patients. HCV@Point of Care CME/CE Author: Nancy Reau, Editor: Paul Kwo Released 2/18/15 https://hepc.atpointofcare.com/web/index.html?page=43&utm_source=activity-announcement&utm_campaign=Hepatitis_C-w7&utm_medium=email-T1a
40. Capitalizing on HCV Advancements: Treatment Management and Benefit Design Strategies for Managed Care — Web Activity. Faculty Nancy Reau and Jeffery Dunn
<http://www.impactedu.net/hcvnexusweb/>
41. Reau N. Hepatitis B. ACP Smart Medicine.
<http://smartmedicine.acponline.org/content.aspx?gbosId=263>. Updated June 4, 2015. doi 10.7326/d476.
42. *Capitalizing on HCV Advancements: Treatment Management and Benefit Design Strategies for Managed Care* Impact Education, CME HCV Release date: March 11, 2015
<http://www.impactedu.net/hcvnexusweb/>
43. **Rapid Response: HCV Updates from Vienna 2015** OpenCME.com. <http://opencme.org/course/rapid-response-hcv-updates-vienna-2015>
44. Saha S and Reau N (2015) Approach to gastrointestinal and liver diseases in pregnancy. In Podolsky DK, Camilleri M, Fitz JG, Kalloo AN, Shanahan F, Wang TC (Eds), *Yamada's Textbook of Gastroenterology 6th Edition*. (pp. 834-858) Wiley-Blackwell. ISBN: 978-1-118-51206-7
45. Nancy Reau and Yannick Bacq (2017). Liver in Pregnancy. In Schiff ER, Maddrey WC, Reddy KR (Eds), *Schiff's Diseases of the Liver, 12th edition*. Wiley-Blackwell. ISBN:978-1-119-25122-4

Abstracts:

1. Reau NS, Senturia YD, LeBailly SA, Christoffel KK. Infant and Toddler Feeding Patterns in Pediatric Practice. Abstract presented for the American Pediatric Society and Society for Pediatric Research Conference in Seattle Washington, May 5, 1994
2. Reau NS, Clark JM, Diehl AM, Magnuson TH. Does diabetes and NASH affect weight loss after bariatric surgery for morbid obesity? Abstract presented at DDW/AASLD May 2002
3. Sotil EU, Jakate S, Reau NS. Metastatic Clear Cell Carcinoma Presenting as Fatty Liver. Abstract ACG October 2004.
4. Levy R, Reau NS, Jensen D. Hepatitis B Practice Treatment Guidelines to Patients Presenting to a Tertiary Care Medical Center. Abstract AASLD October 2004
5. Jung SY, Morrison MJ **Reau NS**. Assessment of awareness level for Hepatitis B in Chicago's Chinatown immigrants and the effectiveness of current intervention programs. Oral presentation and ALF abstract competition 2005
6. Cohen SM, Sotil EU, Woon SE, Savo AM, **Reau NS**, Jensen DM, Lucas TW, Dodson F. Liver Transplantation in Severly Obese Patients: A Single Center Experience. Abstract ACG October 2005
7. Troy TN, O'Brien B, Huo D, Campbell L, Hart J, Reddy G, **Reau N**, Te H, Jensen D, Mohanty S. African Americans with Biopsy-Proven Nonalcoholic Fatty Liver Disease (NAFLD) Have Lower Serum ALT Levels. (A poster presentation at the Digestive Disease Week, Los Angeles, CA, 2006). *Gastroenterology* 2006;130 (Suppl 2):A821.
8. Troy TN, O'Brien B, Huo D, Campbell L, Hart J, Reddy G, **Reau N**, Te H, Jensen D, Mohanty S. African Americans with Biopsy-Proven Nonalcoholic Fatty Liver Disease (NAFLD) Have Less Advanced Histology. (A poster presentation at the Digestive Disease Week, Los Angeles, CA, 2006). *Gastroenterology* 2006;130 (Suppl 2):A823
9. Spangler C, Han S, Morrissey Kwasny M, Cohen SM, **Reau NS**, Jensen DM: Predictors of hemoglobin reduction during first four weeks of Peginterferon alpha-2a/ Ribavirin therapy in chronic hepatitis C. Poster presentation at the Digestive Disease Week May 2006. *Gastroenterology* 2006;130 (Suppl 2):A844
10. **Reau NS**, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with HCV genotype 1 treated with peginterferon alfa-2a (40KD) plus Ribavirin 1000-1200 mg/day. Poster presentation at AASLD 2006. *Hepatology* 2006;44S1:A395.
11. Te HS, Mohanty SR, **Reau N**, Reddy KG, Satoskar R, Jensen DM. Combined liver heart transplantation in the United States. Poster presentation at AASLD 2007. *Hepatology* 2007;46(S1):A561.
12. Satoskar R, Aaronson A, Te HS, Mohanty SR, Reddy KG, **Reau N**, Jensen DM. A nationwide survey of attitudes toward liver transplantation in alcoholic liver disease. . Poster presentation at AASLD 2007. *Hepatology* 2007;46(S1):A563.
13. Reddy KG, Satoskar R, Te HS, **Reau N**, Mohanty SR, DeVoss A, Wherity K, Jensen DM. Candidacy for hepatitis C clinical trials at a tertiary referral center. . Poster presentation at AASLD 2007. *Hepatology* 2007;46(S1):A878.
14. Lee YJ, Jensen DM, Te H, **Reau N**, Reddy KG, Satoskar, RS, Mishra P, Hart J, Mohanty SR. Clinical and Liver Histological Differences in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) with and without Diabetes Mellitus (DM). Poster presentation at DDW 2008. *Gastroenterology*. 2008;4(S1).
15. Marcellin P, Reau N, Ferenci P, Jensen DM. Refined prediction of week 12 response and SVR based on the virological response at week 4 in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®). Poster presentation at AASLD 2008. A1853.
16. **Reau N**, DeVoss C, Elsen C, Te HS, Satoskar R, Mohanty SR, Reddy KG, Jensen DM. Evaluation of Early Null-response (eNR) as a Predictor of Nonresponse to PEG RBV in Patients with HCV. Poster presentation at AASLD 2008. A1247.

17. Te HS, Dasgupta K, Mohanty SR, **Reau N**, Satoskar RS, Cao D, Millis J, Testa G, Reddy K, Jensen DM. Discordance between serum tacrolimus and immunosuppression levels in orthotopic liver transplant (OLT) recipients. Poster presentation at AASLD 2008. A581.
18. Mohanty SR, Lee Y, Mishra P, Hart J, Te HS, **Reau N**, Reddy K, Satoskar RS, Jensen DM. Impact of Metabolic Syndrome on the Progression of Non-alcoholic Fatty Liver Disease (NAFLD). Poster presentation at AASLD 2008. A1158.
19. Marcellin P, Jensen D, **Reau N**, Ferenci P. Categorical response at week 4 allows a refined prediction of week 12 response and sustained virological response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASY) and ribavirin (COPEGUS). Poster Presentation at the 18th Conference of the Asian Pacific Association for the Study of the Liver (APASL) 2008 Seoul Korea.
20. **N. Reau**, R. Satoskar, A. DeVoss, G. Reddy, H. Te, S. Mohanty, L. Espinosa, D. Jensen. Racial differences in globulin levels in patients with hepatitis C and virologic response to pegylated interferon and ribavirin Abstract Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) Copenhagen, Denmark April 23, 2009 A403
http://www.abstractserver.com/easl2009/planner/sp.php?go=abstract&action=abstract_ipanner&absno=2514&EASL2009=qhghorfo6e2u36n50he61opjl1&EASL2009=qhghorfo6e2u36n50he61opjl1
21. A Desai, **N. Reau**, G. Reddy, H. Te, S. Mohanty, R. Satoskar, A. Devoss, D. Jensen Refractory spontaneous bacterial peritonitis: a retrospective study of the university of chicago experience Abstract Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) Copenhagen, Denmark April 23, 2009 A197
http://www.abstractserver.com/easl2009/planner/sp.php?go=abstract&action=abstract_ipanner&absno=453&EASL2009=2iavreosn8njut2amkqs810bb1&EASL2009=2iavreosn8njut2amkqs810bb1
22. D. Jensen, F.M. Hamzeh, E. Lentz, **N. Reau** Identifying patients infected with HCV genotype 1 who may benefit from extended peginterferon alfa-2a/ribavirin therapy beyond 48 weeks Abstract Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) Copenhagen, Denmark April 24, 2009 A620
http://www.abstractserver.com/easl2009/planner/sp.php?go=abstract&action=abstract_ianner&absno=666&EASL2009=7fepvso0s8q1idgn24n6lodob3&EASL2009=7fepvso0s8q1idgn24n6lodob3
23. **Nancy Reau**, Faye M. Hamzeh, Ellen Lentz, Donald M. Jensen Identifying patients infected with hcv genotype 1 who may benefit from extended peginterferon alfa-2a/ribavirin therapy beyond 48 weeks. Poster Presentation at Digestive Disease Week 2009. Chicago IL
24. **Nancy Reau**, Rohit S. Satoskar, L. Espinosa, Amanda K. DeVoss, Helen S. Te, K. G. Reddy, Smruti R. Mohanty, Donald M. Jensen Racial Differences in Globulin Levels in Patients with Hepatitis C and Virologic Response to Pegylated Interferon and Ribavirin. Poster Presentation at Digestive Disease Week 2009. Chicago IL
25. Archita P. Desai, **Nancy Reau**, K. G. Reddy, Helen S. Te, Smruti R. Mohanty² Rohit S. Satoskar, Amanda K. DeVoss, Donald M. Jensen² Refractory Spontaneous Bacterial Peritonitis: A Retrospective Study. Poster Presentation at Digestive Disease Week 2009. Chicago IL
26. Rohit S. Satoskar, Christian A. Mayorga, K. G. Reddy, Smruti R. Mohanty, Helen S. Te, **Nancy Reau**, Donald M. Jensen Adherence to Standard of Care Measures in Suspected Acute Variceal Bleeding. Poster Presentation at Digestive Disease Week 2009. Chicago IL
27. Te HS, Dasgupta K, Cao D, Satoskar RS, Mohanty SR, **Reau N**, Reddy K, Testa G, Millis JM, Jensen DM. Peripheral CD4+ adenosine triphosphate activity levels allow safe reduction of immuneosuppression in orthotopic liver transplant (OLT) recipients. Poster presentation at AASLD 2009.

28. Te HS, Jenkins ET, Pai R, Hart J, Mohanty SR, **Reau N**, Reddy K, Satoskar RS, Jensen DM. Efficacy and safety of antiviral therapy in chronic hepatitis C (CHC) with autoimmune hepatitis (AIH) features Poster presentation at AASLD 2009. A834
29. **Reau N**, Satoskar RS, Te HS, Mohanty SR, Reddy K, Jensen DM. AFP in viral and non-viral liver disease. Could this help clarify cryptogenic cirrhosis? Poster presentation at AASLD 2009. A1062
30. Desai AP, Hossack J, **Reau N**, Reddy K, Te HS, Mohanty SR, Jensen DM, Satoskar RS. Hospitalists Improve care of inpatients with chronic liver disease. Oral presentation at AASLD 2009. A208.
31. Jenkins ET, Pai R, Hart J, Satoskar RS, Mohanty SR, **Reau N**, Reddy K, Jensen DJ, Te HS. Chronic hepatitis C (CHC) with autoimmune hepatitis (AIH) features is associated with more advanced fibrosis. Poster presentation at AASLD 2009. A1621.
32. Sharabash NM, Jensen DM, Cao D, Reau N, Mohanty SR, Satoskar RS, Reddy K, Hammes MS, Te HS. Fibroscan II (FSII) score overestimates the degree of fibrosis in chronic hepatitis c (CHC) patients with significant renal dysfunction. Poster presentation at AASLD 2009. A1636.
33. **Reau N**, Satoskar RS, Te HS, Mohanty SR, Reddy K, Jensen DM. Adherence to HCC screening guidelines in chronic hepatitis B is hindered by compliance with follow-up. Poster presentation at AASLD 2009. A1788.
34. **Nancy Reau**, Hooman Dehghan, Helen S. Te, Smruti R. Mohanty, K. G. Reddy, Donald M. Jensen. Practitioners Advise Therapy Outside of HBV Treatment Guidelines More Frequently in HBsAg Positive Patients and More Often When Using AASLD Compared to EASL Guidelines. Oral Presentation at Digestive Disease Week 2010. New Orleans, LA
35. [Subtype 1b Does Not Confer a Response Advantage to HCV Infected African American Patients Treated with PEG+RBV](#) Erin T. Jenkins¹, **Nancy Reau**, Andrew Aronsohn², Smruti R. Mohanty², Helen S. Te², K. G. Reddy², Donald M. Jensen². Poster Presentation at EASL 2011. Berlin
36. Excessive reduction in hvpig is predictive of mortality after transjugular intrahepatic portosystemic shunt (TIPS). Banerjee S, Lang GD, Aronsohn A, Van Ha T, Te H, **Reau N**, Reddy G, Mohnaty S, Jensen D. EASL 2011. Berlin. Journal of Hepatology Vol. 54 Supplement 1, Page S64
37. Lang G, Banerjee S, Van Ha T, **Reau N**, et al. Diastolic dysfunction predicts mortality after transjugular intrahepatic portosystemic shunt (tips) creation. EASL 2011. Berlin. Journal of Hepatology Vol. 54Supplement 1, Page S73
38. [Diastolic Dysfunction Predicts Mortality After Transjugular Intrahepatic Portosystemic Shunt Creation](#) Gabriel Lang¹, Stacy Banerjee¹, Thuong VanHa², Helen S. Te³, **Nancy Reau**³, Donald M. Jensen³. Poster Presentation at Digestive Disease Week 2011. Chicago IL
39. [Following AASLD Guidelines for HCC Screening in HBV Is Limited By Adherence and Results in Additional Tests with Potential Radiation Risk](#) Christie Choi, **Nancy Reau**, Krysta Drop, Helen S. Te, Andrew Aronsohn, Smruti R. Mohanty, Donald M. Jensen Poster Presentation at Digestive Disease Week 2011. Chicago IL
40. Aronsohn A, **Reau N**, Te HS, Reddy KG, Jensen DM. IL28B Gene polymorphism status does not predict advanced fibrosis in patients with genotype 1 Hepatitis C. The Liver Meeting 2011: 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Abstract 400
41. Jenkins ET, Pai R, Hart J, **Reau N**, Mohanty SR, et al. Autoimmune hepatitis (AIH) in African Americans (AA): Clinical features and response to therapy. The Liver Meeting 2011: 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Abstract 1180
42. **Reau N**, Aronsohn A, Te HS, et al. Managing physician, not patient factors, predict hepatocellular carcinoma (HCC) screening outcomes. The Liver Meeting 2011: 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Abstract 2239.
43. Gaetano JN, Choi CP, Te H, Aronsohn A, Reddy KG, Jensen DM, **Reau NS**. Divergence from AASLD HCC Surveillance Guidelines Leads to Unnecessary Testing and Radiation Exposure.

- Poster Presentation at EASL 2012 Abstract 706 Journal of Hepatology Vol. 56Supplement 2, Page S279
44. John N. Gaetano, Christie Choi, Helen Te, Andrew Aronsohn, K.G. Reddy, Helen TeDonald M. Jensen. Divergence from AASLD HCC Surveillance Guidelines Leads to Unnecessary Testing and Radiation Exposure. Poster Presentation. DDW 2012 Su1229. Gastroenterology Vol 142(5)S-455
 45. Archita P. Desai, Melanie Samardzija, Nancy Reau, Andrew Aronsohn, K.G. Reddy, Donald M. Jensen, Nancy Reau. Divergence from AASLD HCC Surveillance Guidelines Leads to Unnecessary Testing and Radiation Exposure. Poster Presentation. DDW 2012 Su1229. Gastroenterology Vol 142(5)S-455
 46. High-Risk Allografts are a Cost-Effective Mechanism for Decreasing Wait List Mortality *Archita P. Desai; Helen S. Te; Andrew Aronsohn; K. Gautham Reddy; **Nancy Reau**; Donald M. Jensen; J. Michael Millis; John F. Renz* Poster Presentation at AASLD 2012 Boston A306
 47. Protein Biomarkers serve as a signature for Hepatocellular carcinoma (HCC) ***Nancy Reau**; Daniel Schabacker; Timothy Barder; Sang Mee Lee; Glenn Randall; Donald M. Jensen* Poster Presentation at AASLD 2012 Boston A614
 48. **Nancy Reau**, Eli J. Korner, Jian Han, Donald Jensen. Anemia predicts sustained virological response in cirrhotic and non-cirrhotic CHC patients treated with peginterferon alfa-2a and ribavirin in four clinical trials. Poster Presentation at EASL 2013 Amsterdam
 49. RJ Firpi, **NS Reau**, EJ Korner, RS Hoop, J Han, A Mangia, P Ferenci, GT Everson. Factors associated with intolerance to peginterferon alfa/ribavirin in treatment-naïve, cirrhotic/noncirrhotic hepatitis C virus (HCV) genotype 1–infected patients: analysis of data from the multinational PROPHECY cohorts. Poster Presentation at EASL 2013 Amsterdam
 50. **Nancy Reau**, Eli J. Korner, Jian Han, Donald Jensen. . Anemia predicts sustained virologic response in cirrhotic and non-cirrhotic CHC patients treated with peginterferon alfa-2a/ribavirin in four clinical trials. Poster Presentation APASL 2013 Singapore
 51. Bhan J, Smyth C, Sulkes D, Muyl J, Sorokina T, **Reau N**. HCV Patients with Diabetes Have Significantly Higher Average APRI Compared with Nondiabetic HCV Patients: Results of a National Lab Test Database Analysis. Poster Presentation AASLD 2013 Washington DC. Abstract #2242
 52. A. P. Desai*; G. L. Davis; **N. Reau**; D. M. Jensen. Predicting Utilization of Liver Transplantation for Hepatitis C-related Liver Disease in the United States. Poster Presentation AASLD 2013 Washington DC. Abstract #1427
 53. N. H. Afdhal*; **N. Reau**; G. T. Everson; G. Morelli; A. S. Lok; K. E. Sherman; R. C. Dickson; F. Regenstein; E. A. Mena; T. Stewart; M. W. Fried; P. J. Pockros. 1865 Safety and Efficacy of Telaprevir (TVR) or Boceprevir (BOC) in Patients with Cirrhosis: Interim Results of a Longitudinal, Observational Study. Poster Presentation AASLD 2013 Washington DC. Abstract #1865
 54. Smyth C, Sulkes D, Bhan, J, Muyl JC, Sorokina T, Hirji RK, Dhaliwal AS, **Reau N**. HCV Screening of the “Baby Boomer: Generation Increased Significantly Following 2012 CDC Call to Action: Results of a National Lab Test Database Analysis. Poster Presentation DDW 2014 Chicago IL. Abstract#Su1039.
 55. Janardhan SV, Morris J, Desai AP, Te HS, **Reau N**, Reddy KG, Jensen DM, Aronsohn A. Non Liver Disease-Related Factors Significantly Impact “Liver Disease-Specific” Quality of Life Scores From the Chronic Liver Disease Questionnaire (CLDQ). Poster Presentation DDW 2014 Chicago IL. Abstract#Tu1002.
 56. Heiner Wedemeyer¹, Xavier Forns², Antonio Craxi³, **Nancy Reau**⁴, Paul Kwo⁵, Stefan Bourgeois⁶, Michael Bennett⁷, Stephen Ryder⁸, Dominique Larrey⁹, David Mutimer¹⁰, Sandra Lovell¹¹, Manal Abunimeh¹¹, Marcos Pedrosa¹¹, Roger Trinh¹¹ SAFETY COMPARISON OF 12- AND 24-WEEK TREATMENTS IN HCV GENOTYPE 1-INFECTED PATIENTS WITH

CIRRHOSIS: RESULTS FROM TURQUOISE-II. Poster Presentation UEG14ABS-1616 Vienna, Austria October 2014

57. **Nancy Reau, MD**, Paul Kwo, MD, Michael Bennett, MD, Heiner Wedemeyer, MD, Xavier Forns, MD, PhD, Antonio Craxi, MD, Stefan Bourgeois, MD, Stephen Ryder, MD, Dominique Larrey, MD, David Mutimer, MD, Sandra Lovell, PhD, Manal Abunimeh, BSN, Marcos Pedrosa, MD, PhD, Roger Trinh, MD, MPH. Safety Comparison of 12- and 24-Week Treatments in HCV Genotype 1-Infected Patients With Cirrhosis: Results From Turquoise-II. ACG Annual Meeting Poster Presentation Philadelphia PA October 27, 2014
58. Michael W Fried, Xavier Forns, **Nancy Reau**, Heiner Wedemeyer, Mitchell L Shiffman, et al. TURQUOISE-II: Regimens of ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-infected Patients with Cirrhosis, Regardless of Baseline Characteristics. Oral Presentation. AASLD 2014 Boston MA. Abstract #81.
59. John N Gaetano, Dejan Micic, Archita P Desai, Andrew Aronsohn, **Nancy Reau**, Helen Te, K Gautham Reddy, Donald M Jensen. Benefit of Paracentesis on In-hospital Mortality Among Adults Admitted with Cirrhosis and Ascites. Oral Presentation. AASLD 2014 Boston MA. Abstract #91.
60. Nicole M Welch, Andrew Aronsohn, K Gautham Reddy, **Nancy Reau**, Donald Jensen, Helen S Te. Hepatic Sarcoidosis: To treat or not to treat? Poster Presentation. AASLD 2014 Boston MA. Abstract #316.
61. Carol Smyth, Jason Bhan, Tatiana Sorokina, Ajitpal S Dhaliwal, **Nancy Reau**. HCV Screening of “Baby Boomers” Increased Significantly Following 2012 CDC Call to Action, But Screening Rate Fell in Non-Baby Boomers: Results of a Nationwide Lab Test Database Analysis. Poster Presentation. AASLD 2014 Boston MA. Abstract #1447.
62. Mansi Kothari, Archita P Desai, Andrew Aronsohn, K. Gautham Reddy, Donald M Jensen, Helen S Te, **Nancy Reau**. CDC guidelines for hepatitis C screening have no impact on screening or linkage to care. Poster Presentation. AASLD 2014 Boston MA. Abstract #1549.
63. **Nancy Reau**, Tara G Edmonds, Jennifer Garick, Catherine C Capparelli, Simi Hurst. Personalized Learning: A Novel Educational Model to Prepare and Expand the Hepatitis C Workforce. Poster Presentation. AASLD 2014 Boston MA. Abstract #1566.
64. **Nancy Reau**, Catherine C Capparelli, Jennifer Garick, Wendy Cerenzio, Simi Hurst. Effectiveness of an Online, Tailored CME Curriculum on Chronic Hepatitis B Virus (CHB) Management. Poster Presentation. AASLD 2014 Boston MA. Abstract #1686.
65. **Reau N**, Fried MW, Wedemeyer H, Cooper C, et al. HIGH SVR RATES DESPITE MULTIPLE NEGATIVE PREDICTORS IN GENOTYPE 1 PATIENTS RECEIVING OMBITASVIR/PARITAPREVIR/R, DASABUVIR WITH OR WITHOUT RIBAVIRIN FOR 12 AND 24 WEEKS: INTEGRATED ANALYSIS OF SIX PHASE 3 TRIALS. EASL 2015 Vienna Austria. Abstract #95887.
66. **Reau, N**, Bissonnette M, Barder TJ, Schabacker D, Forrester S, Jensen DM. PROTEIN BIOMARKERS REACTIVE WITH HCC SERA SERVE AS A SIGNATURE FOR HEPATOCELLULAR CARCINOMA (HCC). EASL 2015 Vienna Austria. Abstract #95651.
67. Reddy KR, Beavers KL, Gordon S, Harrison S, **Reau N**, et al. EFFECT OF BASELINE FACTORS ON RESPONSE TO THE FIXED-DOSE COMBINATION OF DACLATASVIR (DCV), ASUNAPREVIR (ASV) AND BECLABUVIR (BCV) IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 INFECTION. EASL 2015 Vienna Austria. Abstract #P0889.
68. Oral Presentation: Digestive Disease Week (DDW) 2015
Reau N, Fried MW, Wedemeyer H, Cooper C, et al. HIGH SVR RATES DESPITE MULTIPLE NEGATIVE PREDICTORS IN GENOTYPE 1 PATIENTS RECEIVING OMBITASVIR/PARITAPREVIR/R, DASABUVIR WITH OR WITHOUT RIBAVIRIN FOR 12 AND 24 WEEKS: INTEGRATED ANALYSIS OF SIX PHASE 3 TRIALS.

69. **Reau, N**, Bissonnette M, Barder TJ, Schabacker D, Forrester S, Jensen DM. Protein Biomarkers reactive with Hepatocellular carcinoma (HCC) sera serve as a signature for Hepatocellular carcinoma. Sa1848. Poster Presentation Digestive Disease Week (DDW) 2015 Washington DC
70. Carol Smyth, Jason Bhan, Tatiana Sorokina, Andrea Parker, Ajitpal S. Dhaliwal, **Nancy Reau**. Positivity Rates and Genotype Results in “Baby Boomers” Screened for HCV Following the 2012 CDC Call to Action: Results from a Nationwide Lab Test Database. Tu1048 Poster of Distinction. Digestive Disease Week (DDW) 2015 Washington DC
71. Corlan O. Adebajo, Andrew Aronsohn, Helen S. Te, K. G. Reddy, Donald M. Jensen, **Nancy Reau**. Birth cohort HCV screening at is lower in the Emergency Department than the outpatient setting. Tu1066. Poster Presentation Digestive Disease Week (DDW) 2015 Washington DC.
72. Wedemeyer H, Forns X, Craxi A, **Reau N**, Kwo P, et al. Safety Comparison of 12- and 24- week treatments in HCV genotype 1-infected patients with cirrhosis: Results from TURQUOISE-II. Presented at the Singapore Hepatitis Conference and the Best of EASL 2015, 5–6 June 2015, Suntec, Singapore
73. J-F Dufour H. Wedemeyer, DE Bernstein, M. Colombo, M. Romero-Gomez, **N. Reau**, R. Trinh, W. Xie, J. V. Enejosa, D. E. Cohen, M. Martinez, I. M. Jacobson 99.7% SUSTAINED VIROLOGIC RESPONSE RATE IN 369 HCV GENOTYPE 1B-INFECTED PATIENTS TREATED WITH LABEL-RECOMMENDED REGIMEN OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR WITH OR WITHOUT RIBAVIRIN UEG15-ABS-2709. Presented at United European Gastroenterology Week (UEG) Week 2015 Barcelona, Spain.
74. **Nancy Reau**, Michael W Fried, Heiner Wedemeyer, Curtis Cooper, Moises Diago, et al. High SVR rates despite multiple negative predictors in genotype 2 patients receiving Ombitasvir/Paritaprevir/r, Dasabuvir with or without ribavirin for 12 and 24 weeks: Integrated analysis of six phase 3 trials. Oral presentation The Liver Week 2015 Busan, Korea June 18, 2015.
75. Andrew J Muir, **Nancy Reau***, Paul J Pockros, K Rajender Reddy, Marcos Pedrosa, Lois Larsen, Jeffrey Enejosa, Charles D Howell. High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r+Dasabuvir±Ribavirin: Integrated Safety and Efficacy Analysis. Oral Presentation ACG November 2015 Honolulu, HI
76. Mitchell L Shiffman, Vinod Rustgi, Michael Bennett, Xavier Forns, Tarik Asselah, Ramon Planas Vila, Marcos Pedrosa, Guy Neff, Ronald D’Amico, Li Liu, Juan Carlos Lopez-Talavera, **Nancy Reau**. Efficacy of Ombitasvir/Paritaprevir/r and Dasabuvir +/- Ribavirin in Patients Receiving Concomitant Acid-Reducing Agents in Phase 3 Trials. Presented at the American College of Gastroenterology 80th Annual Meeting, 16-21 October 2015, Honolulu, HI, USA
77. Tien S. Dong, Andrew I. Aronsohn, **Nancy Reau**, K. Gautham Reddy, Helen S. Te. Chronic Rifaximin Therapy Decreases the Risk and Severity of Hepatorenal Syndrome in Cirrhosis. Abstract 271: Presented at the American Association for the Study of Liver Diseases Annual Liver Meeting, November 2015, San Francisco, USA
78. Sujit V. Janardhan, Jason Morris, David G. Beiser, **Nancy Reau**. Diminished Health-Related Quality of Life is an Independent Predictor of Hospitalization in Patients with Cirrhosis. Abstract 521: Presented at the American Association for the Study of Liver Diseases Annual Liver Meeting, November 2015, San Francisco, USA
79. Mark S. Sulkowski, Norbert Brau Eric Lawitz Mitchell L. Shiffman William J. Towner Peter J. Ruane Brian Doehle Jing Wang John McNally Anu Osinusi Diana M. Brainard John G. McHutchison **Nancy Reau** Keyur Patel. A Randomized Controlled Trial of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 12 Weeks in Genotype 2 HCV Infected Patients: The Phase 3 ASTRAL-2 Study. Oral Abstract Parallel 30

- (205): Presented at the American Association for the Study of Liver Diseases Annual Liver Meeting, November 2015, San Francisco, USA
80. Corlan Adebajo, Andrew I. Aronsohn, K. Gautham Reddy, Helen S. Te, Donald M. Jensen, **Nancy Reau**: Age, race and insurance status predict successful screening for HCV-Ab in an academic outpatient setting. Abstract 539: Presented at the American Association for the Study of Liver Diseases Annual Liver Meeting, November 2015, San Francisco, USA
 81. Adam E. Mikolajczyk, Jeanne M. Farnan, John F. McConville, Donald M. Jensen, K. Gautham Reddy, **Nancy Reau**, Helen S. Te, Andrew I. Aronsohn. Learning the Liver: The Pilot Implementation of Hepatology-Focused Educational Interventions in Internal Medicine Residency Training. Abstract 544: Presented at the American Association for the Study of Liver Diseases Annual Liver Meeting, November 2015, San Francisco, USA
 82. John N. Gaetano, K. Gautham Reddy, Andrew I. Aronsohn, Helen S. Te, **Nancy Reau**. Disparities in the Quality of Death and Resource Utilization in End-Stage Liver Disease. Abstract 553: Presented at the American Association for the Study of Liver Diseases Annual Liver Meeting, November 2015, San Francisco, USA
 83. **Nancy Reau**, Fred Poordad Jeffrey Enejosa Asma Siddique Humberto I. Aguilar Jacob P. Lalezari Franco Felizarta Peter J. Ruane Peter Varunok David Bernstein Douglas Dieterich Gregory T. Everson Yiran Hu Greg Ball Tami Pilot-Matias Nancy Shulman Sanjeev Arora. Preliminary Safety and Efficacy Results from TOPAZ-II: A Phase 3b Study Evaluating Long-Term Clinical Out-comes in HCV Genotype 1-infected Patients Receiving Ombitasvir/Paritaprevir/r and Dasabuvir +/-Ribavirin. Abstract 1065: Presented at the American Association for the Study of Liver Diseases Annual Liver Meeting, November 2015, San Francisco, USA
 84. W. Ray Kim **Nancy Reau** Mitchell L. Shiffman Henri Cournand Tarek I. Hassanein. Policy Implications of Disproportionate Burden of Hepatitis C Care for Medicaid Compared to Commercial Payers. Abstract 1813: Presented at the American Association for the Study of Liver Diseases Annual Liver Meeting, November 2015, San Francisco, USA
 85. **Nancy Reau**, et al. *Sofosbuvir/Velpatasvir for 12 wks vs Sofosbuvir+Ribavirin for 24 wks in GT 3 HCV Patients: The Phase 3 ASTRAL-3 Study* for oral presentation. Abstract, 33. The International Association of Providers of AIDS Care (IAPAC), 5th International Conference on Viral Hepatitis. San Francisco CA 3/2016
 86. **Nancy Reau**, et al. *A single tablet regimen of ledipasvir + sofosbuvir is efficacious and well-tolerated among people receiving opiate substitution therapy for oral presentation*. Abstract, 22. The International Association of Providers of AIDS Care (IAPAC), 5th International Conference on Viral Hepatitis. San Francisco CA 3/2016
 87. Lawitz E, Kowdley K, Curry M, **Reau N**, Nguyen M et al. High efficacy of sofosbuvir/velpatasvir plus GS-9857 for 12 weeks in treatment-experienced genotype 1-6 HCV-infected patients, including those previously treated with direct-acting antivirals. Oral Presentation International Liver Congress 2016 -51st annual meeting of the European Association for the Study of the Liver April 2016, Barcelona Spain. Abstract #PS008.
 88. Hezode C, Reau N, Svarovskaia E, Doehle BP, et al. Resistance analysis in 1284 patients with genotype 1 to 6 HCV infection treated with Sofosbuvir/Velpatasvir in the phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4 studies. Poster Presentation International Liver Congress 2016 -51st annual meeting of the European Association for the Study of the Liver April 2016, Barcelona Spain. Abstract #THU-216.
 89. Gane EJ, Nguyen M, Kwo P, Kowdley K, Reau N, et al. Short duration treatment with Sofosbuvir/Velpatasvir Plus GS-9857 in treatment-naïve genotype 106 HCV-Infected patients with or without cirrhosis. Poster Presentation International Liver Congress 2016 -51st annual meeting of the European Association for the Study of the Liver April 2016, Barcelona Spain. Abstract #SAT-138.

90. Reau N et al. [Ribavirin-Free Regimen With Velpatasvir and Sofosbuvir is Associated With High Efficiency and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From ASTRAL-2 and 3 Clinical Trials](#). Oral Presentation; Plenary Session DDW 2016 San Diego CA
91. Reau N, et al. Sof/VEL for 12 Weeks Results in High SVR 12 Rates in Subjects With Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy From the ASTRAL-1, ASTRAL-2 and ASTRAL-3 Studies. Poster of distinction. DDW 2016 San Diego CA.
92. Reau N, et al. Integrated Resistance Analyses of HCV-infected Patients treated with Sofosbuvir, Velpatasvir and Voxilaprevir for 8 and 12 weeks from Phase 2 Studies. Poster of distinction. Abstract 846 AASLD 2016 Boston MA
93. Reau N, et al. Concomitant Proton Pump Inhibitor Use Does Not Reduce the Efficacy of Elbasvir/Grazoprevir. Poster of distinction. Abstract 869 AASLD 2016 Boston MA
94. Sise ME, Alkhouri N, Borg BB, et al Reau N. Use of Ledipasvir/Sofosbuvir (LDV/SOF) in Patients with Advanced Chronic Kidney Disease (eGFR \leq 30ml/min): A case Series. Abstract 1951 AASLD 2016 Boston MA
95. Safety and Efficacy of Velpatasvir and Sofosbuvir with or without Ribavirin for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study. Poster Presentation EASL 2017 Amsterdam
96. Sise ME, Alkhouri N, Borg BB... Reau N. Use of Ledipasvir/Sofosbuvir in Patients with Advanced Chronic Kidney Disease: A Case Series. Poster SAT-234 EASL 2017 Amsterdam
97. Reau N, Vekeman F, Wu E, Bao Y, Sanchez Gonzalez Y. The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: real-world evidence from the United States. Poster SAT-216. EASL 2017 Amsterdam
98. Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, et al. MAGELLAN-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Liver or Renal Transplant Adults with Chronic Hepatitis C Genotype 1-6 Infection. LBO-007. Oral Presentation EASL 2017 Amsterdam
99. Pol et al. Oral presentation Reau, N: Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis c virus genotype 1-6 as a function of chronic kidney disease stage: an integrated analysis. DDW 2017 Chicago IL
100. Sterling RK, Amador J, Stewart P, Lok AS, Di Bisceglie A, Fried MW, Reddy RK, **Reau N**, Nelson DR, Sarkar S, Lim JK, Harlan WR, King W, Golin CE, Evon DM (2017). [HIV Testing in Patients Starting HCV Treatment and Factors Associated with Adherence to AASLD-IDSA Guidelines](#). Poster presented at the annual meeting of the American Association for the Study of Liver Disease, Washington, DC. Abstract published in Hepatology, 66, 1, (Suppl), page 531A. 1 page.
101. Evon DM, Stewart P, Amador J, Alston S, Fried MW, Golin CE, Reeve B, Sterling RK, Lok AS, Di Bisceglie AM, Reddy KR, Nelson DR, **Reau N**, Sarkar S, Lim JK, Harlan WR, King W (2017). [Baseline Characteristics and Patient-Reported Outcomes \(PROs\) from PROP UP: A Large US Multi-Site Observational Study of Patients with Chronic Hepatitis C \(HCV\) Initiating Direct Acting Antiviral \(DAA\) Therapy](#). Poster presented at the annual meeting of the American Association for the Study of Liver Disease, Washington, DC. Abstract published in Hepatology, 66, 1, (Suppl), page 610A. 1 page.
102. **Nancy Reau**¹, Sammy Saab², Lee F. Allen³, Kavita Aggarwal³, Michael Vredenburg³, Ray Kim⁴ Avatrombopag Decreases Need for Platelet Transfusion in Patients with Chronic Liver Disease (CLD) and Thrombocytopenia (TCP) Undergoing Medical Procedures with Low to High Associated Bleeding Risks. Poster Presentation. EASL 2018 Paris